documents incorporated reference document part annual report stockholders fiscal year parts ii ended december proxy statement annual meeting part iii stockholders held april part item business merck co inc company global researchdriven pharmaceutical products services company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures provides pharmacy benefit management services medco health solutions inc medco health companys operations principally managed products services basis comprised two reportable segments merck pharmaceutical includes products marketed either directly joint ventures medco health merck pharmaceutical products consist therapeutic preventive agents sold prescription treatment prevention human disorders medco health revenues consist principally sales prescription drugs managed prescription drug programs either home delivery pharmacies network contractually affiliated retail pharmacies well services provided programs help clients control cost enhance quality prescription drug benefits offered members following table shows sales various categories companys products services millions atherosclerosis hypertensionheart failure antiinflammatoryanalgesics osteoporosis respiratory vaccinesbiologicals antibacterialantifungal ophthalmologicals urology human immunodeficiency virus hiv medco health total beginning sales individual therapeutic class presented net rebates discounts amounts previously presented gross basis whereby rebates discounts included rebates discounts always included total net sales change presentation effect consolidated sales net income sales individual therapeutic class presented comparable basis human health products include therapeutic preventive agents generally sold prescription treatment human disorders among atherosclerosis products zocor simvastatin largestselling hypertensionheart failure products significant cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate prinivil lisinopril antiinflammatoryanalgesics includes vioxx rofecoxib arcoxia etoricoxib agents specifically inhibit cox enzyme responsible pain inflammation osteoporosis product fosamax alendronate sodium treatment prevention osteoporosis respiratory product singulair montelukast sodium leukotriene receptor antagonist vaccinesbiologicals varivax varicella virus vaccine live live virus vaccine prevention chickenpox mmr ii measles mumps rubella virus vaccine live recombivax hb hepatitis b vaccine recombinant largestselling antibacterialantifungal products includes primaxin imipenem cilastatin sodium cancidas caspofungin acetate well recently launched invanz ertapenem sodium ophthalmologicals cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution largestselling urology product proscar finasteride treatment symptomatic benign prostate enlargement hiv products includes crixivan indinavir sulfate protease inhibitor treatment human immunodeficiency viral infection adults primarily includes sales human pharmaceuticals also net rebates discounts pharmaceutical animal health supply sales companys joint ventures astrazeneca lp prilosec omeprazole nexium esomeprazole magnesium significant medco health primarily includes medco health sales nonmerck products medco health pharmacy benefit services principally sales prescription drugs managed prescription drug programs well services provided programs help clients control cost enhance quality prescription drug benefits members january company announced plans establish medco health separate publiclytraded company medco health converted limited liability company delaware corporation may changed name merckmedco managed care llc medco health solutions inc july company announced due solely market conditions postponing initial public offering ipo shares medco health withdrew associated equity registration statement company remains fully committed establishment medco health separate publiclytraded company intends complete separation mid subject market conditions september us food drug administration fda approved cozaar companys angiotensin ii antagonist treatment high blood pressure reduce rate progression nephropathy kidney disease type diabetic patients hypertension nephropathy elevated serum creatinine proteinuria also company submitted supplemental new drug application fda cozaar based results losartan intervention endpoint reduction hypertension life study life study use cozaar significantly reduced combined risk cardiovascular morbidity mortality notably stroke patients hypertension left ventricular hypertrophy compared betablocker atenolol however analysis treatment effect ethnicity black patients treated atenolol lower risk experiencing cardiovascular death heart attack stroke compared patients treated cozaar even though drugs lowered blood pressure similar degree july fda approved new mg oral granule formulation singulair treatment asthma patients ages one two december fda approved singulair relief symptoms seasonal allergic rhinitis adults children young two years age january fda approved cancidas companys oncedaily intravenous antifungal medicine treatment candidemia bloodstream infection following candida infections intraabdominal abscesses peritonitis infections within lining abdominal cavity pleural space infections infections within lining lung acquisitions july company acquired rosetta inpharmatics inc publiclyheld washington based informational genomics company designs develops unique technologies efficiently analyze gene data predict medical compounds interact different kinds cells body january company wholly owned subsidiary msd japan co ltd launched tender offer acquire estimated aggregate purchase price billion remaining common shares banyu pharmaceutical co ltd banyu already tender offer conditional company receiving least million common shares bring share ownership banyu approximately march company announced close final count shares tender offer remaining shares banyu company received tenders shares bringing ownership outstanding banyu common stock japan worlds second largest pharmaceutical market joint ventures company entered agreement astra ab astra develop market astra products united states company astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining company astra restructured joint venture whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership company maintains limited partner interest partnership renamed astrazeneca lp became exclusive distributor products kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing companys share undistributed partnership gaap earnings conjunction restructuring payment million astra purchased option buy companys interest kbi products excluding companys interest gastrointestinal medicines prilosec nexium company also granted astra option shares option buy companys common stock interest kbi exercise price based net present value estimated future net sales prilosec nexium april astra merged zeneca group plc forming astrazeneca ab astrazeneca result merger exchange companys relinquishment rights future astra products existing pending us patents time merger astra paid million subject trueup calculation may require repayment portion amount merger also triggers partial redemption companys limited partner interest furthermore result merger astrazenecas option buy companys interest kbi products exercisable company right require astrazeneca purchase interest addition shares option exercisable two years astras purchase companys interest kbi products company formed joint venture johnson johnson develop market manufacture consumer health care products united states owned joint venture expanded europe canada european extension currently markets sells overthecounter pharmaceutical products france germany italy spain united kingdom significant joint venture products pepcid ac famotidine overthecounter form companys ulcer medication pepcid famotidine well pepcid complete overthecounter product combines companys ulcer medication antacids calcium carbonate magnesium hydroxide effective april company merck vaccine division connaught laboratories inc aventis pasteur affiliate aventis ag agreed collaborate development marketing combination pediatric vaccines promote selected vaccines united states research marketing collaboration enables companies pool resources expedite development vaccines combining several different antigens protect children variety diseases including haemophilus influenzae type b hepatitis b diphtheria tetanus pertussis poliomyelitis combination vaccine development efforts continue agreement vaccines currently promoted company merck vaccine division pasteur mrieux connaught aventis pasteur formed joint venture market human vaccines europe collaborate development combination vaccines distribution european union eu european free trade association company aventis pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc aventis pasteur msd snc joint venture subject monitoring eu partners made certain undertakings return exemption european competition law effective december joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden united kingdom distributors rest europe company rhnepoulenc sa combined respective animal health poultry genetics businesses form merial limited merial fullyintegrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species december rhnepoulenc sas interest merial acquired aventis sa corporation formed merger rhnepoulenc sa hoechst ag may company scheringplough corporation scheringplough entered agreements create separate equally owned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas december company scheringplough announced worldwide expansion excluding japan cholesterolmanagement partnership also december entity merckscheringplough pharmaceuticals partnership submitted new drug application nda fda zetia ezetimibe tablets cholesterol absorption inhibitor discovered scheringplough administered alone statins reduction elevated cholesterol levels october merckscheringplough pharmaceuticals announced fda approval zetia oncedaily tablet zetia mg approved use either together statin reduce ldl cholesterol total cholesterol patients high cholesterol marketing approval received october germany brand name ezetrol use alone marketed statins treatment elevated cholesterol levels march merckscheringplough pharmaceuticals announced ezetrol successfully completed european union mutual recognition procedure mrp completion mrp process eu member states well iceland norway grant national marketing authorization unified labeling ezetrol eu ezetrol indicated coadministration statin adjunctive therapy diet use patients primary hypercholesterolemia appropriately controlled statin alone ezetrol monotherapy indicated adjunctive therapy diet use patients primary hypercholesterolemia statin considered inappropriate tolerated addition ezetrol monotherapy indicated adjunctive therapy diet use patients homozygous familial sitosterolemia coadministered statin use patients homozygous familial hypercholesterolemia partnerships also pursuing development marketing zetia oncedaily combination tablet zocor january merckscheringplough pharmaceuticals reported results phase iii clinical trials fixedcombination tablet containing singulair claritin scheringploughs nonsedating antihistamine demonstrate sufficient added benefits treatment seasonal allergic rhinitis competition markets companys pharmaceutical business conducted highly competitive often highly regulated competition involves intensive search technological innovations ability market innovations effectively longstanding emphasis research development company well prepared compete search technological innovations additional resources meet competition include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products joint ventures licenses refining sales marketing efforts address changing industry conditions enhance product portfolio company continues pursue external alliances earlystage latestage product opportunities including joint ventures targeted acquisitions however introduction new products processes competitors may result price reductions product replacements even products protected patents example number compounds available treat diseases typically increases time resulted slowing growth sales certain companys products addition particularly area human pharmaceutical products legislation enacted states us allows encourages instances absence specific instructions prescribing physician mandates use generic products containing active chemical innovators product rather brand name products governmental pressures toward dispensing generic products significantly reduced sales certain companys products longer protected patents vasotec vaseretic enalapril maleate combination hydrochlorothiazide us rights sold prinivil prinzide lisinopril combination hydrochlorothiazide pepcid mevacor lovastatin slowed growth certain products medco health operates competitive market characterized increasing pricing margin pressures clients seek control growth cost providing prescription drug benefits members medco health competes primarily basis ability provide sophisticated programs services clients members pharmacy benefit plans well physicians pharmacies members use medco healths programs services help clients control cost enhance quality prescription drug benefits offers members medco health accomplishes primarily negotiating competitive pricing pharmaceutical manufacturers retail pharmacies administering prescriptions filled national network retail pharmacies home delivery pharmacies distribution company sells human health products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions companys professional representatives communicate effectiveness safety value companys products health care professionals private practice group practices managed care organizations medco health sells pharmacy benefit management services blue crossblue shield plans managed care organizations insurance carriers thirdparty benefit plan administrators employers federal state local government agencies unionsponsored benefit plans raw materials raw materials supplies normally available quantities adequate meet needs companys business government regulation investigation pharmaceutical industry subject global regulation regional country state local agencies particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states food drug administration modernization act passed culmination comprehensive legislative reform effort designed streamline regulatory procedures within fda improve regulation drugs medical devices food legislation principally designed ensure timely availability safe effective drugs biologics expediting premarket review process new products key provision legislation reauthorization prescription drug user fee act permits continued collection user fees prescription drug manufacturers augment fda resources earmarked review human drug applications helps provide resources necessary ensure prompt approval safe effective new drugs recent years increasing number legislative proposals introduced proposed congress state legislatures would effect major changes health care system either nationally state level legislative initiatives introduced congress include prescription drug benefit proposals medicare beneficiaries although reform bill enacted federal level states passed reform legislation federal state developments expected although company well positioned respond evolving market forces predict outcome effect legislation resulting reform efforts many years pharmaceutical industry pharmacy benefit management business federal state oversight new drug approval system drug safety advertising promotion drug purchasing reimbursement programs formularies variously review company believes continue able conduct operations including introduction new drugs market regulatory environment one type federal initiative contain federal health care spending prospective capitated payment system first implemented reduce rate growth medicare reimbursement hospitals system establishes advance flat rate reimbursement health care patients payer fiscally responsible type payment system cost containment systems widely used public private payers caused hospitals health maintenance organizations customers company costconscious treatment decisions including decisions regarding medicines made available patients company continues work private federal employers slow increases health care costs companys efforts demonstrate medicines help save costs areas pricing flexibility across product portfolio encouraged use companys medicines helped offset effects increasing cost pressures also federal state governments pursued methods directly reduce cost drugs pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense initiatives states seek rebates beyond minimum required medicaid legislation cases patients beyond eligible medicaid federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children company awarded cdc contracts supply six pediatric vaccines program monovalent component certain vaccines outside united states company encounters similar regulatory legislative issues countries business primary thrust governmental inquiry action toward determining drug safety effectiveness often mechanisms controlling prices prescription drugs profits prescription drug companies eu adopted directives concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use companys policies procedures already consistent substance directives consequently believed material effect companys business company subject jurisdiction various regulatory agencies therefore subject potential administrative actions actions may include seizures products civil criminal sanctions certain circumstances company may deem advisable initiate product recalls company believes able compete effectively within environment addition certain countries within eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives european commission proposals complete single market pharmaceuticals improve competitive climate variety means including market deregulation increasing amount focus privacy issues countries around world including united states eu united states federal state governments pursued legislative regulatory initiatives regarding patient privacy including federal recently issued state privacy regulations concerning health information affected companys operations particularly medco health extensive federal state regulations applicable practice pharmacy administration managed health care programs state medco health operates pharmacy laws regulations governing operation licensing standards professional practice pharmacists regulations issued administrative body state typically pharmacy board empowered impose sanctions noncompliance policies procedures medco health comply regulations patents trademarks licenses patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance date grant legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage patent portfolios developed products introduced company normally provide market exclusivity basic patents effect following major products united states aggrastat tirofiban hydrochloride arcoxia cancidas comvax haemophilus b conjugate hepatitis b recombinant vaccine cosopt cozaar crixivan fosamax hyzaar invanz maxalt rizatriptan benzoate pedvaxhib haemophilus b conjugate vaccine primaxin propecia finasteride proscar recombivax hb singulair timopticxe timolol maleate ophthalmic gel forming solution trusopt vioxx zocor basic patent also effect united states zetia developed merckscheringplough pharmaceuticals partnership basic patent also effect sustivastocrin efavirenz bristol myers squibb exclusive license company sells sustiva united states canada certain european countries company markets stocrin countries throughout world zocor lose basic patent protection canada certain countries europe including united kingdom germany company expects decline zocor sales countries fda modernization act modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions reauthorized october best pharmaceuticals children act passed january fda granted additional six months market exclusivity united states cozaar february singulair august zocor june expiration product patent normally results loss market exclusivity covered product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states market exclusivity may available federal law effect product patent expiration also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalties received patent knowhow licenses rights amounted million company also paid royalties amounting million patent knowhow licenses holds divestitures company sold us rights vasotec vaseretic vasotec iv injection enalaprilat biovail laboratories incorporated biovail subsidiary biovail corporation time companys canadian subsidiary merck frosst canada co merck frosst biovail entered supply agreement merck frosst agreed supply biovail minimum five years bulk tablets formulated enalapril maleate enalapril maleate combination hydrochlorothiazide distribution biovail united states vasotec vaseretic basic product patents vasotec vaseretic expired united states prior transactions research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities expenditures companys research development programs billion billion billion estimated grow fullyear expense company maintains ongoing commitment research broad range therapeutic areas clinical development support new products total expenditures period exceeded billion compound annual growth rate company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development projects related human health carried various fields bacterial viral infections cardiovascular functions cancer diabetes pain inflammation kidney function obesity mental health nervous system ophthalmic research prostate therapy respiratory system fungal diseases bone diseases endoparasitic ectoparasitic diseases companion animal diseases production improvement development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug may marketed united states recorded data preclinical clinical experience included nda biological product license application fda required approval development certain products also subject government regulations covering safety efficacy united states many foreign countries assurance compound result particular program obtain regulatory approvals necessary marketed february company announced discontinuing phase ii clinical trials lead gabaa aa agonist compound treatment generalized anxiety company continuing research field anxiety ongoing study gaba agonist molecules timing development molecules certain february banyu announced change timing respect filing japan nda rofecoxib vioxx press release banyu stated reviewing clinical data accumulated date recommendation organization pharmaceutical safety research banyu agreed conduct additional studies japanese patients support nda filing result decision nda filing originally planned take place end march delayed banyu stated conduct additional studies appropriate support filing product new product candidates resulting companys research development programs include arcoxia second cox specific inhibitor potentially useful treatment osteoarthritis rheumatoid arthritis acute pain chronic pain dysmenorrhea company filed nda fda august march company withdrew original us nda investigational medicine company announced june plans refile expanded nda arcoxia fda second half company plans seek indications ankylosing spondylitis chronic autoimmune disease primarily involving spine osteoarthritis rheumatoid arthritis chronic pain dysmenorrhea acute gouty arthritis enhance filing broad range acute pain indications company provide data nda several ongoing studies arcoxia acute pain response fdas request expanded nda also include additional cardiovascular safety data arcoxia versus non naproxen nonsteroidal antiinflammatory drug nsaid company conducting large clinical trials obtain cardiovascular safety data completion european unions mutual recognition procedure excluded france germany national authorizations granted arcoxia remaining eu member states well norway iceland oncedaily treatment osteoarthritis rheumatoid arthritis acute gouty arthritis arcoxia launched countries including several europe latin america asia pacific region expected launched countries throughout france referred cox specific inhibitor compounds coxibs market regulatory review time referral committee proprietary medicinal products european scientific regulatory agency review gastrointestinal cardiovascular safety coxib class transparency commission responsible drug listing pricing reimbursement process france currently reevaluating medical benefit marketed coxibs versus traditional nsaids another product candidate emend aprepitant oral compound potentially useful prevention highly emetogenic chemotherapyinduced nausea vomiting march gastrointestinal drugs advisory committee fda reviewed clinical data emend advisory committee unanimously agreed emend combination standard antiemetic therapy demonstrated efficacy prevention nausea vomiting acute delayed phase following highly emetogenic chemotherapy advisory committee recommended postmarketing studies gather additional information safety profile emend regimen patients receiving certain chemotherapeutic agents advisory committee asked vote whether recommended emend approval products phase iii clinical development include oral compound potentially useful treatment depression neuropsychiatric diseases compound potentially useful treatment diabetic glucose control diabetic dyslipidemia certain new vaccines including human papillomavirus vaccine hpv potentially useful prevent hpv infection rotavirus vaccine potentially useful prevention infant diarrhea dehydration caused rotavirus shingles zoster vaccine potentially useful prevention herpeszoster andor post herpatic neuralgia debilitating pain condition associated zoster competing claims intellectual property hpv field company confident claims delay companys program compound potentially useful treatment chronic obstructive pulmonary disease asthma phase ii clinical development company phase clinical trials vaccine compound potentially useful treatment hivaids addition company demonstrated pharmacological proofofconcept humans key biomarker determining whether move forward clinical development new compounds cancer alzheimers disease obesity diabetes product service marks appearing type form different surrounding text trademarks service marks owned licensed merck co inc subsidiaries affiliates including zetia trademark owned entity merckscheringplough pharmaceuticals partnership cozaar hyzaar registered trademarks ei du pont de nemours company wilmington de claritin trademark schering corporation prilosec nexium trademarks astrazeneca group us trademarks vasotec vaseretic owned biovail laboratories incorporated employees end company employees worldwide employed united states including puerto rico addition medco health employees employed united states approximately worldwide employees company medco health respectively represented various collective bargaining groups environmental matters company believes compliance material respects applicable environmental laws regulations company incurred capital expenditures approximately million environmental protection facilities capital expenditures purpose forecasted exceed million years addition companys operating maintenance expenditures environmental protection facilities approximately million expenditures purpose years forecasted approximate million company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million years amounts consider potential recoveries insurers parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess provided result material adverse effect companys financial position results operations liquidity capital resources cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forward looking statements subject risks uncertainties one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals development programs well proposed initial public offering eventual divestiture medco health subsidiary one must carefully consider statement understand many factors could cause actual results differ companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially although possible predict identify factors may include following generic competition product patents several products recently expired united states countries including product patents mevacor us prinivil prinzide us vaseretic us also zocor lose basic patent protection canada certain countries europe including united kingdom germany addition us patent covering omeprazole active ingredient prilosec company supplies exclusively astrazeneca lp expired trial court held october one generic companys omeprazole product infringe companys formulation patents respect prilosec agreement astrazeneca company receives supply payments predetermined rates us sales certain products astrazeneca notably prilosec nexium company anticipates total supply payments company receives astrazeneca decline midsingle digit percentage rate income contribution related companys collaboration scheringplough continue negative reflects sales ezetimibe offset launch expenses product ongoing joint venture research development spending increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations enforcement thereof affecting companys pharmaceutical vaccine andor pharmacy benefit management businesses efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales legal factors including product liability claims antitrust litigation governmental investigations environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu united states federal state governments pursued legislative regulatory initiatives regarding patient privacy including federal recently issued state privacy regulations concerning health information affected companys operations particularly medco health changes tax laws including changes related taxation foreign earnings well impact legislation capping ultimately repealing section internal revenue code relating earnings companys puerto rican operations changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board securities exchange commission adverse company risk initial public offering divestiture interest medco health may completed due economic stock market conditions generally particularly respect pharmacy benefit management industry tax considerations failure meet customary conditions economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties geographic area segment information companys operations outside united states conducted primarily subsidiaries sales companys human health products subsidiaries outside united states companys human health sales respectively companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions recent years company expanding operations countries located latin america middle east africa eastern europe asia pacific changes government policies economic conditions making possible company earn fair returns business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas operating segments companys business incorporated reference pages beginning caption segment reporting companys annual report stockholders matters board directors company determined dr heidi g miller currently executive vice president chief financial officer bank one corporation previously chief financial officer three different public companies audit committee financial expert board directors made qualitative assessment dr millers level knowledge experience based number factors including formal education experience chief financial officer reporting companies board directors also determined dr miller independent management company make available free charge internet website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act soon reasonably practicable reports electronically filed furnished securities exchange commission companys internet website address wwwmerckcom item properties companys corporate headquarters located whitehouse station new jersey companys pharmaceutical business conducted divisional headquarters located upper gwynedd west point pennsylvania principal research facilities human health products located rahway new jersey west point company also production facilities human health products nine locations united states puerto rico branch warehouses provide services throughout country outside united states subsidiaries company owns interest manufacturing plants properties australia canada countries western europe central south america africa asia medco health operates primary businesses headquarters located franklin lakes new jersey owned leased facilities various locations throughout united states capital expenditures million compared million united states amounted million million abroad expenditures amounted million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company including medco health party number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states alleging conspiracies restraint trade challenging pricing andor purchasing practices company medco health respectively significant number pharmaceutical companies wholesalers also sued similar litigation actions except several actions pending state courts consolidated pretrial purposes united states district court northern district illinois company several defendants finalized agreement settle federal class action alleging conspiracy represents single largest group retail pharmacy claims since time company entered settlements satisfactory terms october judicial panel multidistrict litigation panel determined consolidated pretrial proceedings federal district court chicago substantially completed panel ordered federal antitrust conspiracy cases several settled company returned federal district courts case originally filed cases returned courts many since transferred federal court brooklyn new york proceedings company engaged conspiracy admission wrongdoing made included settlement agreements feasible predict final outcome remaining proceedings opinion company proceedings ultimately result liability would material adverse effect financial position liquidity results operations company previously disclosed company advised us department justice investigating marketing selling activities company pharmaceutical manufacturers company working government respond appropriately informational requests company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels judicial panel multidistrict litigation ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case companys motion dismiss case pending court boston addition company thirty pharmaceutical manufacturers recently named similar complaint filed federal court new york new york county suffolk company believes lawsuits completely without merit vigorously defend january us department justice notified federal court new orleans louisiana going intervene pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleges companys discounting pepcid certain louisiana hospitals led increases costs medicaid company believes complaint completely without merit vigorously defend previously reported dispute company pharmacia corporation pharmacia competing claims patent rights class compounds include rofecoxib active ingredient vioxx settled worldwide basis parties result company maintain worldwide exclusive patent rights vioxx number federal state lawsuits involving individual claims well purported class actions filed company respect vioxx lawsuits also name defendants pfizer inc pharmacia market competing product certain lawsuits include allegations regarding gastrointestinal bleeding cardiovascular events company believes lawsuits completely without merit vigorously defend company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella trivalent vaccines measles mumps rubella including companys mmr ii pharmaceutical companies also sued claimants allege various adverse consequences including autism without inflammatory bowel disease epilepsy diabetes encephalitis encephalopathy chronic fatigue syndrome eight lead cases selected trial scheduled commence april two company six companies trial eight cases initially limited issues causation defect conditions autistic spectrum disorders without inflammatory bowel disease company believes lawsuits completely without merit vigorously defend company also party individual class action product liability lawsuits claims united states involving pediatric vaccines ie hepatitis b vaccine haemophilus influenza type b vaccine contained thimerosal preservative used vaccines defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result thimerosal introduced developing bodies company successful many cases either dismissed stayed ground national vaccine injury compensation program nvicp prohibits person filing maintaining civil action seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims number similar cases mmr ii alone andor thimerosalcontaining vaccines filed united states court federal claims nvicp procedure used process cases contemplates decision general causation issues july company believes lawsuits claims completely without merit vigorously defend proceedings party time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms company products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax prilosec prior expiration companys astrazenecas case prilosec patents concerning products generic companies andas include allegations noninfringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole case alendronate similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products trial united states respect alendronate daily product concluded november november decision issued district court delaware finding companys patent valid infringed appeal filed defendants trial united states involving alendronate weekly product held march decision expected january high court justice england wales held patents company protecting alendronate daily weekly products invalid united kingdom company proceeding appeal decision case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents appeals filed parties trial respect certain generic manufacturers omeprazole products trial date yet set previously disclosed company named defendant number purported class action lawsuits two shareholder derivative actions relating companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits recently class action lawsuits consolidated amended assert claims company medco health certain officers directors relating companys revenue recognition practices retail co payments rebates received medco health medco healths independent status company believes lawsuits completely without merit vigorously defend company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs insurers former site owners operators recalcitrant potentially responsible parties medco health recently company medco health agreed settle class action basis series lawsuits asserting violations employee retirement income security act erisa company medco health certain plaintiffs counsel filed settlement federal district court new york plaintiffs six pharmaceutical benefit plans medco health pharmacy benefit manager filed cases proposed class action settlement agreed plaintiffs five initial six cases gruer cases filed medco health company proposed settlement court yet preliminarily approved company medco health agreed pay million medco health agreed change continue certain specified business practices period five years financial compensation intended benefit members settlement class includes among others erisa plans medco health administered pharmacy benefit time since december settlement preliminarily approved class member plans opportunity participate opt settlement court also schedule hearing purpose determining fairness settlement class members one initial plaintiffs group lawyers filed additional erisa lawsuits company medco health expected oppose settlement settlement becomes final district court grants final approval appeals resolved medco health company agreed proposed settlement order avoid significant cost distraction protracted litigation gruer cases similar claims pharmaceutical benefit managers pending cases alleged medco health treated fiduciary erisa medco health breached fiduciary duty benefit plans amended complaints gruer cases also alleged company medco health violated erisa using medco health increase companys market share entering certain prohibited transactions favor companys products plaintiffs demanded medco health company turn unlawfully obtained profits trust set benefit plans one plaintiffs indicated may amend complaint medco health others allege violations sherman act clayton act various states antitrust laws due alleged conspiracies suppress price competition unlawful combinations allegedly resulting higher pharmaceutical prices similar complaints medco health company also assert claims breach fiduciary duty erisa filed six additional actions plan participants purportedly behalf plans actions similarlysituated self funded plans class action status sought one actions plans could decide opt participate proposed settlement discussed parties lawsuits amended complaint one actions alleges various activities company medco health violate federal state racketeering laws addition proposed class action complaint medco health company also filed trustees one benefit plan complaints actions rely many theories litigation discussed two lawsuits based many allegations also pending medco health federal court california state court new jersey theory liability former action company also defendant based california statute prohibiting unfair business practices plaintiff purports sue behalf general public california seeks injunctive relief disgorgement revenues allegedly improperly received company medco health theory liability new jersey action based new jersey consumer protection statute plaintiff purports represent class similarlysituated non erisa plans seeks compensatory treble damages new jersey court dismissed new jersey action may reinitiated certain circumstances medco health company believe cases completely without merit medco health fiduciary within meaning erisa neither company medco health violated erisa california unfair business practices law new jersey consumer protection law medco health company intend vigorously defend remaining claims previously disclosed august medco health received letter civil division united states attorneys office eastern district pennsylvania relating ongoing investigation pharmacy benefit management industry letter government provided medco health preliminary assessment investigation summarized remedies government could seek could prove violations law companys standpoint letter raise significant new issues also letter government stated preparing decide whether intervene qui tam whistleblower actions pending eastern district pennsylvania medco health previously disclosed governments letter specifically stated issuing formal demand offer settle settlement recommendation medco health believes practices comply legal requirements medco health continuing engage dialogue government respect matter various legal proceedings involving company medco health principally product liability intellectual property suits involving company pending feasible predict outcome proceedings opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company medco health addition time time federal state regulators seek information practices industries company medco health operate feasible predict outcome requests information company medco health expect inquiries material adverse effect financial position liquidity results operations company medco health item submission matters vote security holders applicable executive officers registrant march raymond v gilmartin age june chairman board since november president chief executive officer david w anstice age january president human health responsible companys prescription drug business japan latin america canada australia new zealand companys joint venture relationship scheringplough march president americas us human health responsible one two prescription drug divisions comprising us human health well companys prescription drug business canada latin america companys joint venture relationship scheringplough january president human healththe americas responsible companys human health business united states canada latin america marcia j avedon age january senior vice president human resources september vice president talent management organization effectiveness prior september dr avedon held several senior human resources positions honeywell international diversified manufacturing technology company robert h boisclair age january acting president merck manufacturing division mmd march senior vice president operations americas mmd richard clark age january chairman president chief executive officer medco health solutions inc formerly merckmedco managed care llc medco health whollyowned subsidiary company january president medco health june executive vice presidentchief operating officer medco health celia colbert age january vice president secretary since september assistant general counsel since november caroline dorsa age august vice president treasurer responsible companys treasury tax functions providing financial support merck manufacturing merck research laboratories divisions well human resources september vice president treasurer responsible companys treasury tax functions providing financial support asia pacific division february vice president treasurer responsible companys treasury tax functions january vice president treasurer since january kenneth c frazier age december senior vice president general counsel responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company january vice president deputy general counsel january vice president public affairs since april assistant general counsel responsible public affairs corporate legal activities merck company foundation richard c henriques jr age august vice president controller responsible corporate controllers group providing financial support human health operations united states canada latin america europe middle east africa japan australianew zealand merck vaccine division mvd november vice president controller responsible corporate controllers group providing financial support us human health canada latin america americas mvd february vice president controller responsible corporate controllers group providing financial support americas january vice president controller since january americas peter kim age january president merck research laboratories mrl february executive vice president research development mrl prior february dr kim served member whitehead institute professor biology massachusetts institute technology investigator howard hughes medical institute judy c lewent age january executive vice president chief financial officer president human health asia responsible financial corporate development functions internal auditing corporate licensing companys prescription drug business asia north asia south companys joint venture relationships merck capital ventures llc subsidiary company february executive vice president chief financial officer responsible financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc november senior vice president chief financial officer responsible financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc january senior vice president since january chief financial officer since april responsible financial corporate development functions internal auditing companys joint venture relationships adel mahmoud age may president merck vaccines november executive vice president merck vaccines prior november dr mahmoud john h hord professor chairman department medicine physicianinchief case western reserve university university hospitals cleveland margaret g mcglynn age january president us human health responsible one two prescription drug divisions hospital specialty product franchises comprising us human health ushh managed care group ushh august executive vice president customer marketing sales ushh november senior vice president worldwide human health marketing august senior vice president health utilization management medco health solutions inc whollyowned subsidiary company bradley sheares age january president us human health responsible one two prescription drug divisions primary care product franchises comprising us human health ushh march president us human health responsible one two prescription drug divisions hospital specialty product franchises comprising ushh july vice president hospital marketing sales ushh may vice president antiinfectives therapeutic business group ushh joan e wainwright age january vice president public affairs june vice president corporate communications public affairs prior june ms wainwright deputy commissioner communications us social security administration per woldolsen age january president human healtheurope middle east africa responsible companys prescription drug business europe middle east africa worldwide human health marketing officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board family relationships among officers listed part ii item market registrants common equity related stockholder matters information required item incorporated reference pages companys annual report stockholders item selected financial data information required item incorporated reference data last five fiscal years company included results year yearend position selected financial data table companys annual report stockholders item managements discussion analysis financial condition results operations information required item incorporated reference pages companys annual report stockholders item quantitative qualitative disclosures market risk information required item incorporated reference pages companys annual report stockholders item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income retained earnings comprehensive income cash flows three years period ended december report dated january pricewaterhousecoopers llp independent public accountants copy report dated january previously issued arthur andersen llp independent public accountants incorporated reference pages respectively companys annual report stockholders b supplementary data selected quarterly financial data incorporated reference data contained condensed interim financial data table companys annual report stockholders item changes disagreements accountants accounting financial disclosure february board directors company audit committee dismissed arthur andersen llp arthur andersen aa companys independent public accountants engaged pricewaterhousecoopers llp pwc serve companys independent public accountants fiscal year appointment pwc ratified stockholders companys annual meeting stockholders arthur andersens reports companys consolidated financial statements years ended contain adverse opinion disclaimer opinion qualified modified uncertainty audit scope accounting principles years ended december march disagreements arthur andersen matter accounting principle practice financial statement disclosure auditing scope procedure resolved aas satisfaction would caused make reference subject matter connection report companys consolidated financial statements years reportable events defined item av regulation sk company provided arthur andersen copy foregoing disclosures copy aas letter dated march stating agreement statements incorporated reference exhibit filed annual report fiscal year ended december years ended december date boards decision company consult pwc respect application accounting principles specified transaction either completed proposed type audit opinion might rendered companys consolidated financial statements matters reportable events set forth items ii regulation sk part iii item directors executive officers registrant required information directors nominees incorporated reference pages companys proxy statement annual meeting stockholders held april information executive officers set forth part document pages required information compliance section securities exchange act incorporated reference caption section beneficial ownership reporting compliance companys proxy statement annual meeting stockholders held april item executive compensation information required item incorporated reference pages caption compensation committee interlocks insider participation caption compensation directors beginning caption compensation benefits committee report executive compensation beginning caption annual benefits payable merck co inc retirement plans companys proxy statement annual meeting stockholders held april item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference pages caption security ownership certain beneficial owners management companys proxy statement annual meeting stockholders held april information respect equity compensation plans incorporated reference pages beginning caption equity compensation plan information companys proxy statement annual meeting stockholders held april item certain relationships related transactions information required item incorporated reference caption relationships outside firms pages caption indebtedness management companys proxy statement annual meeting stockholders held april item controls procedures based evaluation date within days filing date companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ac dc securities exchange act amended effective significant changes internal controls factors could significantly affect controls subsequent date evaluation including corrective actions regard significant deficiencies material weaknesses part iv item exhibits financial statement schedules reports form k documents filed part financial statements following consolidated financial statements reports independent public accountants incorporated herein reference companys annual report stockholders noted document consolidated statement income years ended december consolidated statement retained earnings years ended december consolidated statement comprehensive income years ended december consolidated balance sheet december consolidated statement cash flows years ended december notes consolidated financial statements report pricewaterhousecoopers llp independent public accountants copy report dated january previously issued arthur andersen llp independent public accountants financial statement schedules schedules omitted either required applicable financial statements affiliates carried equity basis omitted considered individually aggregate affiliates constitute significant subsidiary exhibits exhibit number description method filing master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission restated certificate incorporation merck co inc september incorporated reference form q quarterly report period ended september bylaws merck co inc amended effective incorporated reference february form q quarterly report period ended march incorporated reference form q quarterly report period ended june exhibit number description method filing executive incentive plan amended effective february incorporated reference annual report fiscal year ended december base salary deferral plan adopted october effective incorporated reference january annual report fiscal year ended december merck co inc deferral program amended restated incorporated reference january registration statement form incentive stock plan amended effective incorporated reference february annual report fiscal year ended december incentive stock plan amended november incorporated reference form q quarterly report period ended june incentive stock plan amended restated incorporated reference february annual report fiscal year ended december nonemployee directors stock option plan amended restated february incorporated reference annual report fiscal year ended december nonemployee directors stock option plan amended incorporated reference april form q quarterly report period ended june nonemployee directors stock option plan amended incorporated reference april form q quarterly report period ended june supplemental retirement plan amended effective incorporated reference january annual report fiscal year ended december retirement plan directors merck co inc amended restated june incorporated reference form q quarterly report period ended june management contract compensatory plan arrangement exhibit number description method filing plan deferred payment directors compensation amended restated filed document january limited liability company agreement merck capital ventures llc dated incorporated reference november annual report fiscal year ended december agreement dated january edward scolnick merck co filed document inc amended restated license option agreement dated july astra ab astra merck inc kbi shares option agreement dated july among astra ab merck co inc merck holdings inc kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc limited partnership agreement dated july kb usa lp kbi sub inc distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp computation ratios earnings fixed charges filed document annual report stockholders portions incorporated reference filed document document deemed filed letter arthur andersen llp securities exchange commission dated incorporated reference march form ka amendment current report form k dated march list subsidiaries filed document consent independent public accountants contained report management contract compensatory plan arrangement incorporated reference form q quarterly report period ended june exhibit number description method filing notice regarding consent arthur andersen llp filed document power attorney filed document certified resolution board directors filed document letter registrant securities exchange commission relating arthur incorporated reference andersen llp annual report fiscal year ended december certification chief executive officer pursuant usc section filed document adopted pursuant section sarbanesoxley act certification chief financial officer pursuant usc section filed document adopted pursuant section sarbanesoxley act none instruments defining rights holders longterm debt company subsidiaries exhibit number filed since total amount securities authorized instruments taken individually exceed total assets company subsidiaries consolidated basis company agrees furnish copy instruments commission upon request copies exhibits may obtained stockholders upon written request directed stockholder services department merck co inc po box ws ab whitehouse station new jersey accompanied check amount payable merck co inc cover processing mailing costs b reports form k threemonth period ended december company furnished five current reports form k item regulation fd disclosure report dated furnished october regarding earnings third quarter certain supplemental information report dated furnished december regarding financial guidance report dated furnished december regarding press release issued medco health solutions inc wholly owned subsidiary registrant report dated furnished december regarding analyst business briefing presentations report dated furnished december regarding companys business briefing analysts signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized ated march merck co inc raymond v gilmartin chairman board president chief executive officer c elia c olbert celia colbert celia colbert attorneyinfact pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signatures title date raymond v gilmartin chairman board president chief march executive officer principal executive officer director judy c lewent executive vice president chief financial officer march president human health asia principal financial officer richard c henriques jr vice president controller principal accounting march officer lawrence bossidy director march william g bowen director march johnnetta b cole director march william daley director march william b harrison jr director march william n kelley director march heidi g miller director march thomas e shenk director march anne tatlock director march samuel thier director march celia colbert signing name hereto hereby sign document pursuant powers attorney duly executed persons named filed securities exchange commission exhibit document behalf persons capacities date stated persons including majority directors company c elia c olbert celia colbert celia colbert attorneyinfact certification raymond v gilmartin certify reviewed annual report merck co inc based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrants certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrants disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrants certifying officers disclosed based recent evaluation registrants auditors audit committee registrants board directors persons performing equivalent functions significant deficiencies design operation internal controls could adversely affect registrants ability record process summarize report financial data identified registrants auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrants internal controls registrants certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses date march r aymond v g ilmartin raymond v gilmartin chairman president chief executive officer certification judy c lewent certify reviewed annual report merck co inc based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrants certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrants disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrants certifying officers disclosed based recent evaluation registrants auditors audit committee registrants board directors persons performing equivalent functions significant deficiencies design operation internal controls could adversely affect registrants ability record process summarize report financial data identified registrants auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrants internal controls registrants certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses date march j udy c l ewent judy c lewent executive vice president chief financial officer president human health asia exhibit consent independent public accountants hereby consent incorporation reference registration statements form nos form nos merck co inc report dated january relating financial statements appears companys annual report stockholders incorporated annual report pricewaterhousecoopers llp florham park new jersey march exhibit index exhibit number description method filing master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission restated certificate incorporation merck co inc incorporated reference form q quarterly september report period ended september bylaws merck co inc amended effective incorporated reference form q quarterly february report period ended march executive incentive plan amended effective incorporated reference annual february report fiscal year ended december base salary deferral plan adopted october incorporated reference annual effective january report fiscal year ended december merck co inc deferral program amended restated incorporated reference registration statement january form incentive stock plan amended effective february incorporated reference annual report fiscal year ended december incentive stock plan amended november incorporated reference form q quarterly report period ended june incentive stock plan amended restated incorporated reference annual february report fiscal year ended december nonemployee directors stock option plan amended incorporated reference annual restated february report fiscal year ended december nonemployee directors stock option plan incorporated reference form q quarterly amended april report period ended june management contract compensatory plan arrangement incorporated reference form q quarterly report period ended june exhibit number description method filing nonemployee directors stock option plan incorporated reference form q quarterly amended april report period ended june supplemental retirement plan amended effective incorporated reference annual january report fiscal year ended december retirement plan directors merck co inc incorporated reference form q quarterly amended restated june report period ended june plan deferred payment directors compensation filed document amended restated january limited liability company agreement merck capital incorporated reference annual ventures llc dated report fiscal year ended december november agreement dated january edward filed document scolnick merck co inc amended restated license option agreement dated july astra ab astra merck inc kbi shares option agreement dated july among astra ab merck co inc merck holdings inc kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc limited partnership agreement dated july kb usa lp kbi sub inc distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp management contract compensatory plan arrangement incorporated reference form q quarterly report period ended june exhibit number description method filing agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp computation ratios earnings fixed charges filed document annual report stockholders portions filed document incorporated reference document deemed filed letter arthur andersen llp securities incorporated reference form ka exchange commission dated march amendment current report form k dated march list subsidiaries filed document consent independent public accountants contained report notice regarding consent arthur andersen llp filed document power attorney filed document certified resolution board directors filed document letter registrant securities exchange incorporated reference annual commission relating arthur andersen llp report fiscal year ended december certification chief executive officer pursuant filed document usc section adopted pursuant section sarbanesoxley act certification chief financial officer pursuant filed document usc section adopted pursuant section sarbanesoxley act incorporated reference form q quarterly report period ended june none instruments defining rights holders longterm debt company subsidiaries exhibit number filed since total amount securities authorized instruments taken individually exceed total assets company subsidiaries consolidated basis company agrees furnish copy instruments commission upon request exhibit merck co inc plan deferred payment directors compensation amended restated january table contents article purpose article ii election deferral measurement methods distribution schedule article iii valuation deferred amounts article iv redesignation within deferral account article v payment deferred amounts article vi designation beneficiary article vii plan amendment termination schedule measurement methods imerck co inc plan deferred payment directors compensation purpose provide arrangement directors merck co inc current employees may elect voluntarily defer payment annual retainer meeting committee fees termination service director ii value compensation mandatorily deferred behalf ii election deferral measurement methods distribution schedule election voluntary deferral amount prior december year director entitled make irrevocable election defer termination service director receipt payment retainer months beginning april next calendar year b committee chairperson retainer beginning april next calendar year c meeting committee fees months beginning april next calendar year prior commencement duties director director newly elected appointed board calendar year must make election paragraph portion voluntary deferral amount applicable directors first year service part thereof voluntary deferral amount shall credited follows meeting committee fees deferred credited day directors services rendered board retainer andor committee chairperson retainer deferred prorata share deferred retainer credited last business day calendar quarter dates voluntary deferral amount parts thereof credited directors deferred account hereinafter referred voluntary deferral dates b mandatory deferral amount friday following companys annual meeting stockholders friday hereinafter referred mandatory deferral date director credited amount equivalent onethird annual cash retainer month period beginning april preceding annual meeting mandatory deferral amount mandatory deferral amount measured merck common stock account director newly elected appointed board mandatory deferral date credited pro rata portion mandatory deferral amount applicable directors first year service part thereof pro rata portion shall credited directors account first day directors service c election measurement method annual election referred section shall include election measurement method methods value amounts deferred measured accordance article iii available measurement methods set forth schedule hereto election distribution schedule annual election referred section shall also include election receive payment following termination service director voluntary deferral amounts mandatory deferral amounts lump sum either immediately one year termination quarterly annual installments five ten fifteen years iii valuation deferred amounts common stock initial crediting annual mandatory deferral amount shall used determine number full partial shares merck common stock amount would purchase closing price common stock new york stock exchange mandatory deferral date portion voluntary deferral amount allocated merck common stock shall used determine number full partial shares merck common stock amount would purchase closing price common stock new york stock exchange applicable voluntary deferral date however determined committee directors board directors measurement merck common stock mandatory voluntary deferral date would constitute fair market value committee shall decide date fair market value shall determined using valuation method set forth article iii section time deferral period shares merck common stock purchased earmarked deferred amounts rights shareholder exist respect amounts dividends directors account credited additional number full partial shares merck common stock would purchasable dividends shares previously credited account closing price common stock new york stock exchange date dividend paid distributions distribution merck common stock account valued closing price merck common stock new york stock exchange distribution date b mutual funds initial crediting amount allocated mutual fund shall used determine full partial mutual fund shares amount would purchase closing net asset value mutual fund shares mandatory voluntary deferral date whichever applicable directors account credited number full partial mutual fund shares determined time deferral period mutual fund shares purchased earmarked deferred amounts rights shareholder exist respect amounts dividends directors account credited additional number full partial mutual fund shares would purchasable closing net asset value mutual fund shares date dividend paid mutual fund shares dividends would paid number shares previously credited account including pro rata dividends partial shares distributions mutual fund distributions valued based closing net asset value mutual fund shares distribution date c adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company mutual fund number kind shares units investment measurement method available plan credited directors account shall adjusted accordingly iv redesignation within deferral account general director may request change measurement methods used value portion hisher account merck common stock amounts deferred using merck common stock method earnings attributable deferrals may redesignated change effective day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed b redesignation may occur active service limit number times director may redesignate portion hisher deferred account permitted redesignated request shall irrevocable designated whole percentages dollar amount death following death director legal representative beneficiary director may redesignate subject rules active directors set forth article iv section b c valuation amounts redesignated portion directors account redesignated valued cash equivalent cash equivalent converted shares units measurement methods purposes redesignations cash equivalent value mutual fund shares shall closing net asset value mutual fund day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed v payment deferred amounts payment payments directors amounts deferred cash accordance distribution schedule elected director pursuant article ii section distributions shall pro rata measurement method distributions shall valued fifteenth day distribution month day business day next business day paid soon thereafter possible b changes distribution schedule prior termination upon request director made time calendar year immediately preceding calendar year service director expected terminate committee directors board directors committee directors sole discretion may authorize extension payment period beyond originally elected director exceed otherwise allowable article ii section andor b payment frequency different originally elected director request may made regard amounts deferred december using merck common stock method earnings attributable deferrals deferrals merck common stock made december earnings thereon may distributed accordance schedule elected director article ii section determined committee directors article vi c posttermination changes distribution schedule following termination service director director may make one request extension period distribution hisher deferred compensation request must received committee directors prior first distribution participant hisher previously elected distribution schedule revised distribution schedule may exceed deferral period otherwise allowable article ii section c request may granted new payment schedule determined sole discretion committee directors request may made regard amounts deferred december using merck common stock method earnings attributable deferrals retired director subject us income tax may petition committee directors change payment frequency including lump sum distribution committee directors may grant petition discretion considers reasonable justification therefor deferrals merck common stock made december earnings thereon may distributed accordance schedule elected director article ii section determined committee directors article vi forfeitures directors deferred amount attributable mandatory deferral amount earnings thereon shall forfeited upon removal director upon determination committee directors sole discretion director joined board managed operated participated material way entered employment performed consulting services otherwise connected material manner company corporation enterprise firm limited partnership partnership person sole proprietorship business entity determined committee directors sole discretion competitive business company subsidiaries affiliates competitor ii directly indirectly acquired equity interest five percent greater competitor iii disclosed material trade secrets material confidential information including customer lists relating company business company others including competitor vi designation beneficiary event death director deferred amount date death shall paid last named beneficiary beneficiaries designated director beneficiary designated directors legal representative one installments committee directors sole discretion may determine vii plan amendment termination committee directors shall right amend terminate plan time reason schedule measurement methods january january merck common stock mutual funds american century emerging markets fund american century europacific growth fund fidelity destiny fidelity dividend growth fidelity equity income fund fidelity lowpriced stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity fund putnam international voyager putnam vista rowe price blue chip growth fund vanguard asset allocation september september investment briefly named putnam global growth fund result merger september putnam global equity fund putnam global growth fund merged fund briefly retained name putnam global growth fund effective october merged fund changed name putnam global equity fund schedule measurement methods effective january merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn class z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international voyager putnam vista rowe price blue chip growth vanguard asset allocation exhibit agreement whereas dr edward scolnick dr scolnick expressed interest relinquishing executive duties devoting full time research activities remaining employed merck co inc merck company whereas merck wishes continue support benefit dr scolnicks outstanding research ability insights knowledge hereby agreed follows change title job responsibilities effective upon close business december dr scolnick voluntarily relinquish positions titles responsibilities mercks executive vice president science technology b president merck research laboratories mrl c member mercks management committee member mrls research management committee e member board directors merck subsidiary unit merck f member merck committee currently serving consideration therefor merck appoint dr scolnick president emeritus mrl effective january capacity dr scolnick report mercks chief executive officer responsible engaging scientific research field choice subject approval president mrl west point laboratory enable dr scolnick engage scientific research president emeritus mrl merck assign laboratory appropriate research mercks facility west point pennsylvania b allot annual budget determined president mrl shall less million supplies equipment materials scientific staff needed laboratory c assign full time administrative assistant dr scolnick responsible administering budget supervising staff beginning later december continuing long laboratory made available paragraph dr scolnick submit mercks board directors annual progress report describing activities results laboratory assigned merck compensation commencing january dr scolnicks base salary per month subject appropriate payroll tax withholding deductions continue eligible participate various employee benefit plans cover mercks salaried exempt employees however eligible aip eip bonus annual stock option grants except subject approval compensation benefits committee mercks board directors dr scolnick eligible receive eip bonus payable performance addition dr scolnick remains employee merck merck allow reasonable use merck corporate aircraft otherwise available attend conferences external board meetings terms conditions employment merck employee dr scolnick employee continue abide bound conditions employment agreement signed copy annexed hereto incorporated herein attachment including limited dr scolnicks promises without authorization disclose confidential information knowledge data property relating belonging merck b engage activity conflicts impairs obligations merck employee c inventions discoveries technical business innovations developed conceived solely jointly others period employment along lines activities operations work investigations employment relates may receive information due employment ii result suggested work may merck shall property merck endeavor assist company obtaining protecting enforcing property ownership rights patents inventions discoveries innovations retirement notwithstanding anything contrary retirement plan salaried employees merck co inc qualified plan merck co inc supplemental retirement plan srp together qualified plan retirement plans dr scolnicks final average compensation term used retirement plans shall less would employment terminated december provided however extent use final average compensation causes increase benefits payable aggregate retirement plans increase shall payable srp b upon termination employment dr scolnick entitled treated retiree mercks welfare pension savings stock option plans deferral program according terms plans effect time time except otherwise specifically provided agreement provided submitted appropriate paperwork required company part retirement process termination employment event merck terminates dr scolnicks employment reason cause provided dr scolnick executes releasewaiver claims noncompetenonsolicitation agreement form satisfactory merck provided dr scolnick violated conditions employment agreement annexed hereto attachment termination employment occurs dr scolnicks th birthday merck shall give onetime grant academic institution designated dr scolnick sole purpose enabling set maintain research laboratory employee institution academic institution must designated dr scolnick within one year termination employment event termination dr scolnicks th birthday merck shall also take whatever steps may necessary ensure dr scolnicks years credited service within meaning retirement plans shall less extent use credited service causes increase benefits payable aggregate retirement plans increase shall payable srp purposes paragraph termination dr scolnicks employment reason cause shall also deemed occur upon dr scolnicks resignation retirement within days merck either advises dr scolnick longer support research dr scolnick laboratory assigned agreement ii reduces annual funding laboratory million effective date agreement become effective upon execution parties subject approval mercks board directors applicable law parties acknowledge dr scolnicks employment relationship merck formed laws state new jersey united states question scope interpretation effect agreement resolved substantive procedural laws state new jersey complete agreement agreement constitutes complete final agreement parties supersedes replaces prior contemporaneous agreements negotiations discussions relating subject matter agreement agreement shall binding upon merck upon dr scolnick including without limitation agreement made hereafter unless single integrated writing titled agreement signed merck dr scolnick merck co inc e dward colnick md r aymond v g ilmartin edward scolnick md raymond v gilmartin dated december dated january exhibit merck co inc subsidiaries computation ratios earnings fixed charges millions except ratio data years ended december income taxes add subtract onethird rents interest expense gross interest capitalized net amortization equity income loss affiliates net distributions preferred stock dividends net tax earnings onethird rents interest expense gross preferred stock dividends fixed charges ratio earnings fixed charges purposes computing ratios earnings consist income taxes onethird rents deemed company representative interest factor inherent rents interest expense net amounts capitalized equity income loss affiliates net distributions dividends preferred stock subsidiary companies fixed charges consist onethird rents interest expense reported companys consolidated financial statements dividends preferred stock subsidiary companiestable contents financial section contents financial review description mercks business competition health care environment business strategies joint ventures equity method affiliates foreign operations operating results capital environmental expenditures analysis liquidity capital resources recently issued accounting standards critical accounting policies matters cautionary factors may affect future results dividends paid per common share condensed interim financial data common stock market prices consolidated statement income consolidated statement retained earnings consolidated statement comprehensive income consolidated balance sheet consolidated statement cash flows notes consolidated financial statements managements report audit committees report compensation benefits committees report reports independent public accountants selected financial data financial review description mercks business merck global researchdriven pharmaceutical products services company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures provides pharmacy benefit management services medco health solutions inc medco health sales millions atherosclerosis hypertensionheart failure antiinflammatoryanalgesics osteoporosis respiratory vaccinesbiologicals antibacterialantifungal ophthalmologicals urology human immunodeficiency virus hiv medco health beginning sales individual therapeutic class presented net rebates discounts amounts previously presented gross basis whereby rebates discounts included rebates discounts always included total net sales change presentation effect consolidated sales net income sales individual therapeutic class presented comparable basis human health products include therapeutic preventive agents generally sold prescription treatment human disorders among atherosclerosis products zocor largestselling hypertensionheart failure products significant cozaar hyzaar vasotec prinivil antiinflammatoryanalgesics includes vioxx arcoxia agents specifically inhibit cox enzyme responsible pain inflammation osteoporosis product fosamax treatment prevention ofosteoporosis respiratory product singulair leukotriene receptor antagonist vaccinesbiologicals varivax merck co inc annual report table contents live virus vaccine prevention chickenpox mmr ii pediatric vaccine measles mumps rubella recombivax hb hepatitis b vaccine recombinant largestselling antibacterialantifungal products includes primaxin cancidas well recently launched invanz ophthalmologicals cosopt trusopt largestselling urology product proscar treatment symptomatic benign prostate enlargement hiv products includes crixivan protease inhibitor treatment human immunodeficiency viral infection adults primarily includes sales human pharmaceuticals also net rebates discounts pharmaceutical animal health supply sales companys joint ventures astrazeneca lp azlp prilosec nexium significant medco health primarily includes medco health sales nonmerck products medco health pharmacy benefit services principally sales prescription drugs managed prescription drug programs well services provided programs help clients control cost enhance quality prescription drug benefits members merck sells human health products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions companys professional representatives communicate effectiveness safety value products health care professionals private practice group practices managed care organizations competition health care environment markets company conducts business highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access united states company working private government employers slow increase health care costs demonstrating companys medicines help save costs areas pricing flexibly across product portfolio encouraged growing use medicines helped offset effects increasing cost pressures legislative bodies continue work expand health care access reduce associated costs initiatives include prescription drug benefit proposals medicare beneficiaries introduced us congress outside united states difficult environments encumbered government cost containment actions company worked payers help allocate scarce resources optimize health care outcomes limiting potentially detrimental effects government actions sales growth addition countries within european union eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives european commission proposals complete single market pharmaceuticals improve competitive climate variety means including market deregulation increasing amount focus privacy issues countries around world including united states eu united states federal state governments pursued legislative regulatory initiatives regarding patient privacy including recently issued federal privacy regulations concerning health information affected companys operations particularly medco health although one predict outcome legislative regulatory advocacy initiatives well positioned respond evolving health care environment market forces anticipate worldwide trend toward costcontainment continue resulting ongoing pressures health care budgets continue successfully launch new products contribute health care debates monitor reforms new products policies strategies enable us maintain strong position changing economic environment business strategies company discovering new innovative products developing new indications existing productsthe result continuing commitment research enhance product portfolio company continues pursue external alliances earlystage latestage product opportunities including joint ventures targeted acquisitions additionally achievement productivity gains become permanent strategy productivity initiatives include manufacturing level optimizing plant utilization implementing lowestcost processes improving technology transfer research manufacturing throughout company reducing cost purchased materials services reengineering core administrative processes streamlining organization manufacturing level company expects productivity gains continue substantially offset inflation product cost core pharmaceuticals business company committed improving access medicines enhancing quality life people around world mercks african comprehensive hivaids partnership botswana collaboration government botswana bill melinda gates foundation striving develop comprehensive sustainable approach hiv prevention care treatment catalyze access hiv medicines developing countries october company announced new mg tablet formulation antiretroviral medicine stocrin introduced price less merck co inc annual report table contents one dollar per day least developed countries hardest hit hivaids epidemic actions merck working partners public private sectors alike focus real barriers access medicines developing world need sustainable financing increased international assistance additional investments education training health infrastructure capacity developing countries merck acquired medco containment services inc renamed merckmedco later medco health medco health provides pharmacy benefit services united states home delivery pharmacies national network retail pharmacies medco health provides sophisticated programs services clients members pharmacy benefit plans well physicians pharmacies members use medco healths programs services help clients control cost enhance quality prescription drug benefits offer members medco healths clients include blue crossblue shield plans managed care organizations insurance carriers thirdparty benefit plan administrators employers federal state local government agencies unionsponsored benefit plans january company announced plans establish medco health separate publiclytraded company medco health converted limited liability company delaware corporation may changed name merckmedco managed care llc medco health solutions inc july company announced due solely market conditions postponing initial public offering ipo shares medco health withdrew associated equity registration statement merck remains fully committed establishment medco health separate publiclytraded company intends complete separation mid subject market conditions january company wholly owned subsidiary msd japan co ltd launched tender offer acquire estimated aggregate purchase price billion remaining common shares banyu pharmaceutical co ltd banyu already tender offer closes march conditional company receiving least million common shares bring share ownership banyu approximately company plans fund transaction cash hand japan worlds second largest pharmaceutical market joint ventures equity method affiliates expand research base realize synergies combining capabilities opportunities assets company formed number joint ventures merck entered agreement astra ab astra develop market astras products royaltybearing license companys total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed november developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby company acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns recorded equity income affiliates aggregated million million million respectively astrazeneca merger triggers partial redemption mercks limited partner interest upon redemption azlp distribute kbi amount based primarily multiple mercks annual revenue derived sales former astra usa inc products three years prior redemption limited partner share agreed value merck co inc annual report table contents conjunction restructuring payment million astra purchased option asset option buy mercks interest kbi products excluding gastrointestinal medicines prilosec nexium asset option exercisable exercise price equal net present value march projected future pretax revenue received company kbi products appraised value merck also right require astra purchase interest appraised value addition company granted astra option buy mercks common stock interest kbi exercise price based net present value estimated future net sales prilosec nexium option exercisable two years astras purchase mercks interest kbi products astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment subject trueup calculation may require repayment portion amount trueup amount directly dependent fair market value astra product rights retained company accordingly recognition contingent income deferred realizable amount determinable anticipated prior provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value payment trueup amount occur astrazenecas purchase mercks interest kbi products contingent upon exercise either mercks option astrazenecas option therefore payment appraised value may may occur merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture expanded europe canada sales joint venture products follows millions gastrointestinal products products merck pasteur mrieux connaught aventis pasteur established owned joint venture market vaccines europe collaborate development combination vaccines distribution europe sales joint venture products follows millions hepatitis vaccines viral vaccines vaccines merck rhnepoulenc aventis combined animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species sales joint venture products follows millions fipronil products avermectin products products may company scheringplough corporation scheringplough entered agreements create separate equally owned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas december cholesterolmanagement partnership agreements expanded include countries world excluding japan october ezetimibe first new class cholesterollowering agents approved us zetiaand germany ezetrol partnerships also pursuing development marketing zetia oncedaily combination tablet zocor sales ezetimibe totaled million january merckscheringplough pharmaceuticals reported results phase iii clinical trials fixed combination tablet containing singulair claritin scheringploughs nonsedating antihistamine demonstrate sufficient added benefits treatment seasonal allergic rhinitis merck co inc annual report table contents foreign operations companys operations outside united states conducted primarily subsidiaries sales merck human health products subsidiaries outside united states merck human health sales respectively companys worldwide business subject risks currency fluctuations governmental actions company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions recent years merck expanding operations countries located latin america middle east africa eastern europe asia pacific changes government policies economic conditions making possible merck earn fair returns businesses developing areas sometimes less stable offer important opportunities growth time operating results total sales increased total volume basis foreign exchange essentially effect sales growth total sales increased total volume basis foreign exchange one point unfavorable effect sales growth sales merck human health products grew foreign exchange rates less half point unfavorable effect sales growth price changes essentially effect sales growth measuring effects changes value foreign currencies calculated net price increases traditionally hyperinflationary countries principally latin america domestic human health sales declined reflecting impact products affected patent expirations wholesaler purchasing behavior affected quarterly sales levels certain products estimated net impact wholesaler buying patterns yearonyear change aggregate domestic sales minimal foreign sales grew including one percentage point unfavorable effect exchange mercks five key human health products zocor vioxx fosamax cozaar hyzaar singulair represent twothirds worldwide human health sales collectively increased sales newer products cancidas invanz experienced unit volume gains mature products maxalt cosopt sales products affected patent expirations including vasotec vaseretic prinivil prinzide pepcid mevacor declined billion total mercks consolidated sales growth also reflected impact medco healths sales increased zocor mercks cholesterolmodifying medicine continued solid performance worldwide sales billion increase excluding estimated impact wholesaler buying patterns yearonyear growth zocor approximated worldwide sales zocor expected approximate billion billion zocor lose basic patent protection canada certain countries europe including united kingdom germany company expects decline zocor sales countrieszocor continues remain therapy choice many physicians proven ability clinical trials act favorably three key lipid parameterslowering bad ldl cholesterol triglycerides raising level good hdl cholesterol clinical trials demonstrated zocor wellestablished safety tolerability profile results landmark heart protection study hps largestever study using cholesterolmodifying medicine showed zocor mg proven save lives reducing risk heart attack stroke broad range highrisk patients including people heart disease people diabetes regardless cholesterol levels supplemental new drug application snda filed third quarter merck co inc annual report table contents us food drug administration fda incorporate data hps us label zocor updated federal guidelines report people diabetes increased risk cardiovascular disease increased number people united states eligible statin therapy additional million vioxx mercks onceaday coxib remains largest prescribed arthritis pain medication across many markets worldwide including europe canada latin america year vioxx sales grew achieving billion sales excluding estimated impact wholesaler buying patterns yearonyear growth vioxx approximated worldwide sales coxibs vioxx arcoxia expected approximate billion billion pain relief gastrointestinal gi safety remain important considerations physicians choosing medication treatment arthritis since gi outcomes data landmark patient vioxx gastrointestinal outcomes research vigor study added labeling vioxx number key managed care accounts vioxx advantaged position among coxibs continues grow million people exclusive preferred access vioxx managed care plans updated analysis combining data clinical trials arthritis patients presented american college rheumatology fourth quarter underscores proven gi safety profile vioxx new data showed vioxx significantly reduced percent incidence confirmed uppergi perforations ulcers bleeds compared four widely used non selective nonsteroidal antiinflammatory drugs nsaids analysis consistent significant reduction clinically important gi events versus naproxen seen vigor study also clinical studies acute pain vioxx demonstrated superior efficacy codeine mg acetaminophen mg well oxycodone mg acetaminophen mg france referred coxibs market currently regulatory review cpmp european scientific regulatory agency discuss gastrointestinal cardiovascular safety coxib class transparency commission responsible pricing reimbursement france seeking evaluate medical benefit currently marketed coxibs versus traditional nsaids mercks new coxib arcoxia launched countries including several europe latin america asiapacific region arcoxia studied broad range indications including osteoarthritis adult rheumatoid arthritis chronic pain acute pain dysmenorrhea menstrual pain acute gouty arthritis company announced june plans refile expanded new drug application nda arcoxia fda second half company plans seek indications ankylosing spondylitis chronic autoimmune disease primarily involving spine osteoarthritis rheumatoid arthritis chronic pain dysmenorrhea acute gouty arthritis enhance filing broad range acute pain indications merck provide data nda several ongoing studies arcoxia acute pain response fdas request expanded nda also include additional cardiovascular safety data arcoxia versus nonnaproxen nsaid merck conducting large clinical trials obtain cardiovascular safety data investigational study released october american college rheumatology arcoxia mg mg daily showed positive results compared placebo treating ankylosing spondylitis posthoc analysis data study arcoxia daily provided improved pain relief compared naproxen mg twice daily six weeks december results study patients acute gouty arthritis showed arcoxia mg daily provided comparable degree pain relief indomethacin mg three times daily completion european unions mutual recognition procedure excluded france germany arcoxia received medical clearance remaining european countries oncedaily treatment osteoarthritis rheumatoid arthritis acute gouty arthritis fosamax leading product worldwide treatment prevention postmenopausal male glucocorticoidinduced osteoporosis continued strong growth sales billion increase estimated net impact wholesaler buying patterns yearonyear fosamax sales growth minimal worldwide sales fosamax expected approximate billion billion fosamax weekly launched markets worldwide continues drive growth large undertreated osteoporosis market around world million postmenopausal women osteoporosis worldwide less percent currently diagnosed treated two studies fosamax presented annual meeting american society bone mineral research september first showed tenyear period fosamax provided continuous increases lumbar spine bone mass second study first headto head study bisphosphonates showed european patients fosamax mg weekly increased lumbar spine hip bone mineral density bmd risedronate mg daily using european dosing regimen cozaar companion agent hyzaar combination cozaar diuretic hydrochlorothiazide prescribed angiotensin ii antagonists aiias worldwide treatment hypertension global sales two products strong reaching billion increase excluding estimated impact wholesaler buying patterns yearonyear growth cozaar hyzaar approximated worldwide sales cozaar hyzaar expected approximate billion billion cozaar experiencing new growth many major markets outside united states based results losartan intervention endpoint reduction hypertension life study announced earlier year life study use cozaar significantly merck co inc annual report table contents reduced combined risk cardiovascular morbidity mortality notably stroke patients hypertension left ventricular hypertrophy lvh compared betablocker atenolol however analysis treatment effect ethnicity black patients treated atenolol lower risk experiencing cardiovascular death heart attack stroke compared patients treated cozaar even though drugs lowered blood pressure similar degree merck submitted supplemental nda cozaar based results life study september fda approved cozaar reduce rate progression nephropathy kidney disease type diabetic patients hypertension nephropathy new indication based reduction endpoint noninsulin dependent diabetes mellitus angiotensin ii antagonist losartan renaal study showed cozaar effect overall mortality significantly delayed progression endstage renal disease esrd condition requiring dialysis kidney transplantation survival merck ei du pont de nemours company dupont began sharing equally operating profits cozaar hyzaar north america terms license agreement established parties financial terms outside north america changed singulair mercks onceaday leukotriene receptor antagonist continued strong performance asthma controller total sales singulair billion increase excluding estimated impact wholesaler buying patterns yearonyear growth singulair approximated worldwide sales singulair expected approximate billion billion singulair prescribed asthma controller among allergists pediatricians united states since launch million prescriptions singulair dispensed patients positive results major european trial involving singulair presented european respiratory society meeting stockholm september european study showed singulair dosed onceaday taken inhaled corticosteroid ics budesonide dosed mg per day least effective controlling asthma budesonide alone double dose mg per day measured morning peak flow rate measure lung function december fda approved singulair relief symptoms seasonal allergic rhinitis also known hay fever adults children young two years age currently available oral allergy medications work blocking histamine one several causes allergy symptoms singulair new different way treat seasonal allergies blocks leukotrienes instead blocking histamine convenient onceaday tablet singulair helps relieve broad range seasonal allergy symptoms hours sales growth also benefited cancidas first new class antifungals called echinocandins glucan synthesis inhibitors introduced decade cancidas used treat certain lifethreatening fungal infections becoming prevalent number people compromised immune systems increases new medicine indicated treatment candidemia bloodstream infection following candida infections intraabdominal abscesses peritonitis infections within lining abdominal cavity pleural space infections infections within lining lung also indicated esophageal candidiasis invasive aspergillosis patients respond tolerate antifungal therapies amphotericin b lipid formulations amphotericin b andor itraconazole products experiencing growth include maxalt treatment acute migraine headaches adults cosopt treat glaucoma recently launched invanz treatment selected moderate severe infection adults crixivan though still contributing sales declined unit volume due therapeutic competition supply sales prilosec nexium azlp also contributed sales total supply sales azlp expected decline midsingle digit percentage rate october merckscheringplough pharmaceuticals announced fda approval zetia ezetimibe first new class cholesterollowering agents inhibits intestinal absorption cholesterol oncedaily tablet zetia mg approved use either together statin reduce ldl cholesterol total cholesterol patients high cholesterol clinical trials zetia showed significant additional reductions ldl cholesterol added dose statin generally well tolerated overall side effect profile similar statin alone initial launch performance united states strong prescriptions written us approval zetia supported nine pivotal phase iii studies evaluating efficacy safety zetia use patients high cholesterol marketing approval received october germany brand name ezetrol use alone marketed statins treatment elevated cholesterol levels approval ezetimibe germany represents first step seeking marketing approval throughout eu mutual recognition procedure company records interest merckscheringplough partnerships equity income affiliates sales merck human health products grew foreign exchange rates three percentage point unfavorable effect sales growth price changes less half point favorable effect growth domestic sales growth foreign sales grew including seven percentage point unfavorable effect exchange unit volume growth sales merck human health products driven five key products zocor vioxx cozaarhyzaar fosamax singulair also contributing mercks human health volume growth proscar maxalt cancidas merck co inc annual report table contents costs expenses millions change change materials production marketing administrative research development equity income affiliates income expense net materials production costs increased compared sales growth rate excluding effect exchange inflation costs increased one point higher unit sales volume growth higher growth rate costs sales volume growth primarily attributable significant growth medco healths historically lowermargin business materials production costs increased compared sales growth rate primarily attributable growth lowermargin medco health business excluding effect exchange inflation costs increased five points higher unit sales volume growth gross margin compared gross margin reductions reflect growth medco health business well effects product mix core pharmaceuticals business company expects manufacturing productivity offset inflation product cost core pharmaceuticals business marketing administrative expenses decreased total volume basis marketing administrative spending reflects impact sales force expansions launch costs support new product introductions new indications well savings operationalefficiency work redesign initiatives reduced companys overall cost structure marketing administrative expenses estimated grow midsingle digit percentage rate fullyear expense marketing administrative expenses increased total essentially level volume basis including one point decrease attributable marketing expenses reflecting success operational efficiency initiatives increased resource commitment mercks five key growth drivers marketing administrative expenses percentage sales continuous improvement ratios primarily reflects lower growth marketing administrative costs relative medco healths sales growth sustained impact operational efficiency initiatives research development expenses increased excluding effects exchange inflation expenses increased research development reflects increased investment later stage products continued significant investment basic research increased well strategic spending outside licensing efforts research development expenses increased excluding effect exchange inflation expenses increased research development pharmaceutical industry inherently longterm process following data show unbroken trend yeartoyear increases companys research development spending period compounded annual growth rate research development research development expenses estimated grow percent full year expense equity income affiliates reflects favorable performance companys joint ventures partnership returns azlp decrease equity income affiliates primarily reflects impact companys share launch expenses zetia ongoing research development expenses associated merckscheringplough merck co inc annual report table contents partnerships contribution collaboration continue negative sales ezetimibe offset launch expenses product ongoing research development spending decrease equity income affiliates primarily reflects impact companys share research development expenses associated merckscheringplough partnerships decrease expense net reflects decreased amortization expense resulting implementation financial accounting standards board statement goodwill intangibles fas goodwill longer amortized lower minority interest expense losses investments decrease expense net primarily attributable higher interest income lower minority interest expense increased gains sales investments decrease partially offset lower exchange gains resulting translation companys balance sheet effect income recorded settlement disputed proceeds related astrazeneca merger earnings millions except per share amounts change change net income sales average total assets earnings per common share assuming dilution companys effective income tax rate consolidated effective income tax rate estimated approximately net income lower net income net income percentage sales compared decline ratios principally due higher growth rate medco healths historically lowermargin business offset part lower growth marketing administrative expenses foreign currency exchange one percentage point unfavorable effect growth rate compared three percentage point unfavorable effect net income percentage average total assets earnings per common share assuming dilution level grew net income earnings per common share assuming dilution reflect benefit implementation fas favorable growth rates earnings per common share assuming dilution compared net income result treasury stock purchases company anticipates fullyear consolidated earnings per common share assuming dilution reflects expectation double digit earnings per share growth core pharmaceuticals business standalone basis includes full year net income medco health companys intention separate medco health business mid subject market conditions remains unchanged separation occurred company adjust consolidated earnings expectations reflect separation appropriate following supplemental information discussion represents core pharmaceuticals business standalone summarized operating results merck excluding medco health standalone summarized operating results medco health combination historical standalone operating results merck medco health equal mercks consolidated operating results certain consolidating adjustments necessary preparation consolidated operating results associated primarily sales merck products medco health related rebates received medco health merck financial information included herein may indicative consolidated operating results either merck medco health future would medco health separate company periods presented statement financial accounting standards accounting impairment disposal longlived assets fas effective company january precludes reporting business distributed stockholders discontinued operations disposal date merck co inc annual report table contents merck co inc core pharmaceuticals business standalone basis millions sales materials production income taxes net income sales mercks core pharmaceuticals business standalone basis grew gross margin compared decrease primarily attributable effect changes product mix net income percentage sales compared reflecting gross margin reduction well continued investment research development medco health standalone basis millions total net revenues total cost revenues income taxes net income medco health continued deliver strong sales growth net revenues reported standalone basis reached billion increase medco health managed million prescriptions year net revenues increase primarily reflects increased prices charged manufacturers increased representation new higher cost drugs brand name prescription base well higher prescription drug utilization medco healths home delivery service largest pharmacy benefit management pbm industry continued expand throughout medco healths home delivery prescriptions year grew million represent percent medco healths total prescription volume medco health experienced percent increase number prescriptions processed member website wwwmedcohealthcom prescription volume million since medco health provided pbm services united health group largest client fiveyear contract revenues united health group represented approximately medco healths net revenues totaled billion billion respectively medco healths gross margin respectively decrease margin reflects impact competitive pricing pressures reduced discounting pharmaceutical manufacturers operating costs resulting new business initiated beginning accordance fas medco healths income taxes net income reflect goodwill amortization totaled million medco healths net income standalone basis estimated grow percent percent fullyear driven primarily increased use generics home delivery well automation capital environmental expenditures capital expenditures billion billion expenditures united states billion billion expenditures included million production facilities million research development facilities million environmental projects million administrative safety general site projects capital expenditures approved yet spent december billion capital expenditures estimated billion company believes compliance material respects applicable environmental laws regulations capital expenditures environmental protection forecasted exceed million years addition companys operating maintenance expenditures pollution control approximately million expenditures purpose years forecasted approximate million expenditures remediation environmental liabilities million estimated million years depreciation billion billion million million respectively applied locations united states merck co inc annual report table contents analysis liquidity capital resources net cash provided operating activities billion cash provided operations continues companys primary source funds finance operating needs capital expenditures cash used fund capital expenditures billion pay company dividends billion partially fund purchase treasury shares december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments totals include billion cash investments held banyu selected data millions working capital total debt total liabilities equity cash provided operations total debt working capital levels adequate meet operating requirements company ratios total debt total liabilities equity cash provided operations total debt reflect strength companys operating cash flows ability company cover contractual obligations companys contractual obligations december follows payments due period millions total loans payable current portion longterm debt longterm debt operating leases loans payable current portion longterm debt includes million notes final maturity annual basis either repurchased holders option remarketing agent remarketed redeemed company loans payable current portion longterm debt also reflects million longdated notes subject repayment option holders annual basis december billion variable rate preferred units issued whollyowned subsidiary redeemable option holders beginning included minority interests companys billion shelf registration statement filed securities exchange commission issuance debt securities became effective company issued million variable rate notes shelf february company issued million tenyear notes million variable rate notes shelf remaining capacity companys shelf registration statement billion companys strong financial position evidenced triplea credit ratings moodys standard poors outstanding debt issues provides high degree flexibility obtaining funds competitive terms ability finance ongoing operations primarily internally generated funds desirable high risks inherent research development required develop market innovative new products highly competitive nature pharmaceutical industry company participate balance sheet arrangements involving unconsolidated subsidiaries provide material source financing potentially expose company material unrecorded financial obligations february board directors approved purchases billion merck shares july board directors also approved purchases time additional billion merck shares company purchased billion treasury shares previously authorized completed programs billion program total treasury stock purchased billion period company purchased million shares total cost billion us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result astrengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated third party sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange merck co inc annual report table contents rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows fully offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value companys hedges would declined million million respectively uniform weakening us dollar december market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck uses purchased local currency put options uniform weakening us dollar yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar last three years program reduced volatility cash flows mitigated loss value cash flows periods relative strength us dollar portion revenues hedged cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets merck routinely enters contracts fully offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts limited basis deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level company also uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly strengthened currency exposures company december income taxes would declined million million respectively merck net long position relative major foreign currencies consideration forward contracts uniform strengthening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows addition revenue hedging balance sheet risk management programs company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk company party two million notional amount payfloating receivefixed interest rate swap contracts designated hedges fair value changes million fiveyear threeyear fixed rate notes attributable changes benchmark libor swap rate swaps effectively convert fixed rate obligations floating rate instruments company also party seven year combined interest rate currency swap contract entered converts variable rate foreign currency denominated investment variable rate us dollar investment swap contract hedges changes fair value investment attributable fluctuations exchange rates allowing company receive variable rate returns cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly impacted changes interest rates market value companys medium longterm fixed rate investments modestly impacted changes us interest rates changes medium longterm us interest rates would significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value companys investments debt merck co inc annual report table contents related swap contracts change interest rates indicated one percentage point increase interest rates december would positively impacted net aggregate market value instruments million million respectively one percentage point decrease december would negatively impacted net aggregate market value million million respectively increased sensitivity companys aggregate investment debt portfolio december reflects decrease weighted average maturity companys investments fair value companys debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair value companys investments determined using combination pricing duration models whereas duration linear approximation works well modest changes yields generates symmetrical result pricing models reflecting convexity priceyield relationship provide greater precision reflect asymmetry price movements interest rate changes opposite directions impact convexity pronounced longerterm maturities low interest rate environments recently issued accounting standards july financial accounting standards board fasb issued statement accounting costs associated exit disposal activities fas effective exit disposal activities initiated december adoption fas requires companies recognize costs associated exit disposal activities incurred rather date commitment exit disposal plan impact companys financial position results operations november fasb issued interpretation guarantors accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin fin requires liability recorded guarantors balance sheet fair value upon issuance guarantee recognition provisions fin effective guarantees issued modified december adoption fin impact companys financial position results operations january fasb issued interpretation consolidation variable interest entities fin fin requires variable interest entity vie consolidated company subject majority risk loss vies activities entitled receive majority entitys residual returns consolidation requirements newlycreated vies transitional disclosure provisions fin effective company immediately adoption fin impact companys financial position results operations critical accounting policies matters consolidated financial statements include certain amounts based managements best estimates judgments estimates used determining items provisions rebates discounts returns income taxes depreciable amortizable lives pension postretirement benefit plan assumptions amounts recorded contingencies environmental liabilities reserves uncertainty inherent estimates actual results may differ estimates company aware reasonably likely events circumstances would result different amounts reported would material impact results operations financial condition application following accounting policies result accounting estimates potential significant impact financial statements revenue recognition merck revenues sales merck human health products recognized upon shipment product revenues recorded net provisions rebates discounts returns established time sale accruals rebates discounts cover discounts result sales merck customer intermediary wholesale purchaser well rebates owed based upon contractual agreements legal requirements benefit providers including medicaid final dispensing product pharmacy benefit plan participant accruals estimated time sale based available information regarding portion sales rebates discounts earned adjusted appropriate specific known events reflecting prevailing contractual discount rate amounts accrued rebates discounts may adjusted trends significant events indicate adjustment appropriate accruals also adjusted reflect actual amounts paid credited upon validation claims data adjustments material results operations medco health medco health revenues consist principally sales prescription drugs managed prescription drug programs either home delivery pharmacies networks contractually affiliated retail pharmacies revenues recognized prescriptions dispensed home delivery pharmacies retail pharmacies contractually affiliated networks medco healths responsibilities client contracts adjudicate member claims properly control clients drug spend separate contractual pricing relationships responsibilities retail pharmacies networks interaction members among indicators qualify medco health principal indicators set forth emerging issues task force issue reporting gross revenue principal vs net agent eitf transactions customers medco healths responsibilities merck co inc annual report table contents client contracts include validating patient member clients plan prescription drug applicable formulary instructing pharmacist prescription price copayment due patient identifying possible adverse drug interactions pharmacist address physician prior dispensing suggesting medically appropriate generic alternatives control drug cost clients members approving prescription dispensing revenues recognized medco healths home delivery pharmacies retail network contracts principal gross reporting basis accordance eitf prescription price ingredient cost plus dispensing fee negotiated clients including portion price settled directly member copayment plus medco healths administrative fees although medco health credit risk respect retail copayments indicators gross treatment present addition copayments viewed mechanism medco health negotiates clients help manage retained prescription drug spending costs level copayments affect medco healths rebates margin transaction retail copayments included medco health revenues cost revenues totaled billion billion billion respectively terms contracts nature medco healths involvement prescription fulfillment process qualify principal eitf revenues transactions consist administrative fee paid medco health clients medco health deducts revenues manufacturers rebates pays clients clients earn rebates medco health estimates rebates periodend based actual estimated claims data estimates portion claims clients earn rebates medco health bases estimates best available data periodend recent history various factors affect amount rebates due client medco health adjusts rebates payable clients actual amounts paid rebates paid generally quarterly basis significant events occur medco health records cumulative effect adjustments revenues identified adjusts estimates prospectively consider recurring matters adjustments generally result contract changes clients differences estimated actual product mix subject rebates whether product included applicable formulary adjustments material results operations medco health also deducts revenues discounts offered payments made clients payments include example implementation allowances payments made risk sharing agreements clients payments related performance guarantees medco health provides implementation allowances clients upon contract initiation capitalizes payments amortizes revenue life contract payments refundable upon cancellation relate noncancelable contracts limited instances medco health enters risksharing agreements whereby agrees share risk clients drug trend increasing certain levels medco health determines regular basis potential deduction revenue comparing clients increase drug spending period specified contractual indexed target rate clients rate increase exceeds target medco health calculates deduction revenue accordance terms contract contractual cap liability medco health manages risk type arrangement restricting number client contracts include risk sharing capping responsibility provisions requiring client implement drug cost management programs accordingly medco healths exposure risksharing arrangements material financial position liquidity rebates receivable pharmaceutical manufacturers earned based upon dispensing prescriptions either home delivery pharmacies pharmacies medco healths retail networks recorded reduction medco healths cost revenues included accounts receivable medco health accrues rebates receivable multiplying estimated rebatable prescription drugs dispensed home delivery pharmacies dispensed one pharmacies retail networks contractually agreed manufacturer rebate amount medco health revises rebates receivable estimates actual difference recorded cost revenues final rebatable prescriptions calculated rebates billed manufacturer generally days subsequent end applicable quarter historically effect adjustments resulting reconciliation rebates recognized recorded actual amounts billed material results operations rebates earned medco health pharmaceutical manufacturers excluding merck totaled billion billion billion respectively rebates received medco health merck accordingly eliminated upon consolidation approximated million million million respectively rebates payable clients estimated accrued concurrently rebates receivable rebates paid clients based actual drug spend quarterly basis collection rebates receivable manufacturers time rebates payable revised reflect amounts due typically medco healths client contracts give client right audit calculation rebates owed client date adjustments related client audits material merck co inc annual report table contents pensions postretirement benefit plans net pension postretirement benefit cost totaled million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated annually modified reflect prevailing market rate december portfolio highquality aa fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december company changed discount rate us pension postretirement benefit plans expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well historical actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weighted average expected longterm rate return targeted portfolio allocated across investment categories result analysis company changed expected rate return us pension postretirement benefit plans targeted investment portfolio companys us pension plans allocated us equities international equities fixed income investments real estate cash investments portfolios equity weighting consistent longterm nature plans benefit obligation expected annual standard deviation returns targeted portfolio approximates reflects equity allocation december cash component actual investment portfolio slightly excess targeted allocation excess subsequently reinvested according targeted allocation holding assumptions constant net pension postretirement benefit cost companys us plans expected increase approximately million approximately million attributable lower discount rate approximately million attributable lower expected rate return actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost company expect minimum pension funding requirement internal revenue code preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions expected returns based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized marketrelated value assets ratably fiveyear period total unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization total unrecognized net losses companys us plans december expected increase net pension postretirement benefit cost approximately million growing million contingencies environmental liabilities merck company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable company including medco health party number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states alleging conspiracies restraint trade challenging pricing andor purchasing practices company medco health respectively significant number pharmaceutical companies wholesalers also sued similar litigation actions except several actions pending state courts consolidated pretrial purposes united states district merck co inc annual report table contents court northern district illinois company several defendants finalized agreement settle federal class action alleging conspiracy represents single largest group retail pharmacy claims since time company entered settlements satisfactory terms october judicial panel multidistrict litigation panel determined consolidated pretrial proceedings federal district court chicago substantially completed panel ordered federal antitrust conspiracy cases several settled company returned federal district courts case originally filed cases returned courts many since transferred federal court brooklyn new york proceedings company engaged conspiracy admission wrongdoing made included settlement agreements feasible predict final outcome remaining proceedings opinion company proceedings ultimately result liability would material adverse effect companys financial position results operations liquidity previously disclosed merck advised us department justice investigating marketing selling activities merck pharmaceutical manufacturers merck working government respond appropriately informational requests company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels judicial panel multidistrict litigation ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like merck defendants prior pending case companys motion dismiss case pending court boston addition merck thirty pharmaceutical manufacturers recently named similar complaint filed federal court new york new york county suffolk company believes lawsuits completely without merit vigorously defend january us department justice notified federal court new orleans louisiana going intervene pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleges mercks discounting pepcid certain louisiana hospitals led increases costs medicaid merck believes complaint completely without merit vigorously defend previously reported dispute merck pharmacia corporation pharmacia competing claims patent rights class compounds include rofecoxib active ingredient vioxx settled worldwide basis parties result company maintain worldwide exclusive patent rights vioxx number federal state lawsuits involving individual claims well purported class actions filed company respect vioxx lawsuits also name defendants pfizer inc pharmacia market competing product lawsuits include allegations regarding gastrointestinal bleeding cardiovascular events company believes lawsuits completely without merit vigorously defend company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella trivalent vaccines measles mumps rubella including companys mmr ii pharmaceutical companies also sued claimants allege various adverse consequences including autism without inflammatory bowel disease epilepsy diabetes encephalitis encephalopathy chronic fatigue syndrome eight lead cases selected trial scheduled commence april two merck six companies trial eight cases initially limited issues causation defect conditions autistic spectrum disorders without inflammatory bowel disease company believes lawsuits completely without merit vigorously defend company also party individual class action product liability lawsuits claims united states involving pediatric vaccines ie hepatitis b vaccine haemophilus influenza type b vaccine contained thimerosal preservative used vaccines defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result thimerosal introduced developing bodies company successful many cases either dismissed stayed ground national vaccine injury compensation program nvicp prohibits person filing maintaining civil action seeking damages vaccine merck co inc annual report table contents manufacturer vaccinerelated injuries unless petition first filed united states court federal claims number similar cases mmr ii alone andor thimerosalcontaining vaccines filed united states court federal claims nvicp procedure used process cases contemplates decision general causation issues july company believes lawsuits claims completely without merit vigorously defend proceedings party time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms company products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market us generic form fosamax alendronate prilosec omeprazole prior expiration companys astrazenecas case prilosec patents concerning products generic companies andas include allegations noninfringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole case alendronate similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products trial us respect alendronate daily product concluded november november decision issued district court delaware finding companys patent valid infringed appeal filed defendants trial us involving alendronate weekly product scheduled commence march january high court justice england wales held patents company protecting alendronate daily weekly products invalid united kingdom company proceeding appeal decision case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents appeals filed parties trial respect certain generic manufacturers omeprazole products trial date yet set previously disclosed company named defendant number purported class action lawsuits two shareholder derivative actions relating companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits five current former members management members board directors also named defendants certain lawsuits company believes lawsuits completely without merit vigorously defend company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties prps may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs worldwide survey initially performed assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated estimates extent contamination site initially made preinvestigation stage liabilities potential cost remediation accrued time definitive information became available course investigations andor remedial efforts site estimates refined accruals adjusted accordingly estimates related accruals continue refined annually managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december december respectively liabilities undiscounted consider potential recoveries insurers parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year merck co inc annual report table contents medco health recently company medco health agreed settle class action basis series lawsuits asserting violations employee retirement income security act erisa company medco health certain plaintiffs counsel filed settlement federal district court new york plaintiffs six pharmaceutical benefit plans medco health pharmacy benefit manager filed cases proposed class action settlement agreed plaintiffs five initial six cases gruer cases filed medco health company proposed settlement court yet preliminarily approved company medco health agreed pay million medco health agreed change continue certain specified business practices period five years financial compensation intended benefit members settlement class includes among others erisa plans medco health administered pharmacy benefit time since december settlement preliminarily approved class member plans opportunity participate opt settlement court also schedule hearing purpose determining fairness settlement class members one initial plaintiffs group lawyers filed additional erisa lawsuits company medco health expected oppose settlement settlement becomes final district court grants final approval appeals resolved medco health company agreed proposed settlement order avoid significant cost distraction protracted litigation gruer cases similar claims pharmaceutical benefit managers pending cases alleged medco health treated fiduciary erisa medco health breached fiduciary duty benefit plans amended complaints gruer cases also alleged company medco health violated erisa using medco health increase companys market share entering certain prohibited transactions favor companys products plaintiffs demanded medco health company turn unlawfully obtained profits trust set benefit plans one plaintiffs indicated may amend complaint medco health others allege violations sherman act clayton act various states antitrust laws due alleged conspiracies suppress price competition unlawful combinations allegedly resulting higher pharmaceutical prices similar complaints medco health company also assert claims breach fiduciary duty erisa filed six additional actions plan participants purportedly behalf plans actions similarlysituated self funded plans class action status sought one actions plans could decide opt participate proposed settlement discussed parties lawsuits amended complaint one actions alleges various activities company medco health violate federal state racketeering laws addition proposed class action complaint medco health company also filed trustees one benefit plan complaints actions rely many theories litigation discussed two lawsuits based many allegations also pending medco health federal court california state court new jersey theory liability former action company also defendant based california statute prohibiting unfair business practices plaintiff purports sue behalf general public california seeks injunctive relief disgorgement revenues allegedly improperly received company medco health theory liability new jersey action based new jersey consumer protection statute plaintiff purports represent class similarlysituated non erisa plans seeks compensatory treble damages new jersey court dismissed new jersey action may reinitiated certain circumstances medco health company believe cases completely without merit medco health fiduciary within meaning erisa neither company medco health violated erisa california unfair business practices law new jersey consumer protection law medco health company intend vigorously defend remaining claims previously disclosed august medco health received letter civil division united states attorneys office eastern district pennsylvania relating ongoing investigation pharmacy benefit management industry letter government provided medco health preliminary assessment investigation summarized remedies government could seek could prove violations law companys standpoint letter raise significant new issues also letter government stated preparing decide whether intervene qui tam whistleblower actions pending eastern district pennsylvania medco health previously disclosed governments letter specifically stated issuing formal demand offer settle settlement recommendation medco health believes practices comply legal requirements medco health continuing engage dialogue government respect matter various legal proceedings involving company medco health principally product liability intellectual property suits involving company pending feasible predict outcome proceedings opinion company proceedings merck co inc annual report table contents either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company medco health addition time time federal state regulators seek information practices industries company medco health operate feasible predict outcome requests information company medco health expect inquiries material adverse effect financial position liquidity results operations company medco health cautionary factors may affect future results annual report written reports oral statements made time time company may contain socalled forward looking statements subject risks uncertainties one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals development programs one must carefully consider statement understand many factors could cause actual results differ companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors described companys filings securities exchange commission especially forms k q k item companys annual report year ended december filed march company discusses detail various important factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act prior filing form k year ended december reference made item companys annual report year ended december one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties dividends paid per common share year th q rd q nd q st q condensed interim financial data millions except per share amounts th q rd q nd q st q sales materials production costs marketing administrative expenses research development expenses equity income affiliates income expense net income taxes net income basic earnings per common share earnings per common share assuming dilution sales materials production costs marketing administrative expenses research development expenses equity income affiliates income expense net income taxes net income basic earnings per common share earnings per common share assuming dilution common stock market prices th q rd q nd q st q high low high low principal market trading common stock new york stock exchange symbol mrk merck co inc annual report table contents consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development equity income affiliates income expense net income taxes taxes income net income basic earnings per common share earnings per common share assuming dilution consolidated statement retained earnings merck co inc subsidiaries years ended december millions balance january net income common stock dividends declared balance december consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income comprehensive income loss net unrealized loss gain derivatives net tax net income realization net unrealized gain investments net tax net income realization minimum pension liability net tax comprehensive income accompanying notes integral part consolidated financial statements merck co inc annual report table contents consolidated balance sheet merck co inc subsidiaries december millions assets current assets cash cash equivalents shortterm investments accounts receivable inventories prepaid expenses taxes total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less allowance depreciation goodwill intangibles net assets liabilities stockholders equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities minority interests stockholders equity common stock one cent par value authorized shares issued shares shares paidin capital retained earnings accumulated comprehensive loss income less treasury stock cost shares shares total stockholders equity accompanying notes integral part consolidated financial statement merck co inc annual report table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization deferred income taxes net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchase securities subsidiaries investments proceeds sale securities subsidiaries investments net cash used investing activities cash flows financing activities net change shortterm borrowings proceeds issuance debt payments debt proceeds issuance preferred units subsidiary purchase treasury stock dividends paid stockholders proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statement merck co inc annual report table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck global researchdriven pharmaceutical products services company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures provides pharmacy benefit management services medco health solutions inc medco health human health products include therapeutic preventive agents generally sold prescription treatment human disorders pharmacy benefit services primarily include sales prescription drugs managed prescription drug programs well services provided programs manage patient health drug utilization summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive third party participating rights consolidated subsidiaries merck ownership less outside stockholders interests shown minority interests investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis foreign currency translation us dollar functional currency companys foreign subsidiaries cash cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories substantially domestic pharmaceutical inventories valued lower lastin firstout lifo cost market book tax purposes medco health inventory foreign pharmaceutical inventories valued lower firstin firstout fifo cost market investments investments classified availableforsale reported fair value unrealized gains losses extent hedged reported net tax minority interests accumulated comprehensive income investments debt securities classified heldto maturity consistent managements intent reported cost impairment losses charged income expense net thantemporary declines fair value company considers available evidence evaluating potential impairment investments including duration extent fair value less cost companys ability intent hold investment revenue recognition revenues sales merck human health products recognized upon shipment product revenues recorded net provisions rebates discounts returns established time sale medco health revenues consist principally sales prescription drugs managed prescription drug programs either home delivery pharmacies networks contractually affiliated retail pharmacies recognized prescriptions dispensed medco health evaluates client contracts using indicators emerging issues task force issue reporting gross revenue principal vs net agent determine whether acts principal agent fulfillment prescriptions retail pharmacy network medco health acts principal revenues recognized gross reporting basis prescription price ingredient cost plus dispensing fee negotiated clients including portion price allocated client settled directly member copayment medco health separate contractual relationships clients pharmacies b responsible validate economically manage claim claims adjudication process c commits set prescription prices pharmacy including instructing pharmacy price settled copayment requirements manages overall prescription drug relationship patients e credit risk price due client medco health adjudicates prescriptions pharmacies contract directly client financial risks medco health revenue recorded using net reporting service revenues amount administrative fee earned medco health processing claim rebates guarantees risksharing payments paid clients discounts deducted revenue earned client contractual payments made clients generally made upon initiation contracts implementation allowances may example designated clients funding costs transition plans medco health compensation certain data licensing rights granted client medco health medco health considers payments integral part pricing contract believes represent variability timing cash flow change underlying economics contract accordingly payments capitalized amortized reduction revenue straightline basis life contract payments refundable upon cancellation merck co inc annual report table contents contract relate noncancelable contracts amounts capitalized assessed periodically recoverability based profitability contract medco health revenues also include service revenues consisting principally administrative fees earned clients non product related service revenues including sales data pharmaceutical manufacturers health care organizations administrative fees earned services comprised claims processing eligibility management benefits management pharmacy network management related customer services recognized prescription dispensed nonproduct related service revenues recorded medco health performance occurs collectibility assured depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings goodwill intangibles goodwill represents excess acquisition costs fair value net assets businesses purchased effective january company adopted provisions statement financial accounting standards goodwill intangible assets fas addresses recognition measurement goodwill intangibles subsequent business combination accordance fas goodwill associated acquisitions subsequent june amortized see note effective january goodwill existing june amortized rather assigned reporting units within companys segments evaluated impairment least annual basis using fair value based test amortization expense goodwill recorded reported net income would increased million basic earnings per common share earnings per common share assuming dilution million basic earnings per common share earnings per common share assuming dilution respectively company completed transitional annual impairment tests determined goodwill impaired provisions new guidance acquired intangibles recorded cost amortized straightline basis estimated useful lives see note events circumstances warrant review company assess recoverability future operations intangibles using undiscounted cash flows derived lowest appropriate asset groupings generally subsidiary level impairments recognized operating results extent carrying value exceeds fair value determined based net present value estimated future cash flows stockbased compensation employee stockbased compensation recognized using intrinsic value method generally employee stock options granted purchase shares company stock fair market value time grant accordingly compensation expense recognized companys stockbased compensation plans employee performancebased awards options granted employees certain equity method investees total significant effect net income earnings per common share company applied fair value method recognizing employee stockbased compensation follows years ended december net income reported compensation expense net tax reported fas pro forma net income earnings per common share basicas reported basicpro forma assuming dilutionas reported assuming dilutionpro forma average fair value employee nonemployee director options granted respectively fair value estimated using blackscholes optionpricing model based weighted average market price grant date following weighted average assumptions years ended december dividend yield riskfree interest rate volatility expected life years use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used determining items provisions rebates discounts returns income taxes depreciable amortizable lives pension postretirement benefit plan assumptions amounts recorded contingencies environmental liabilities reserves uncertainty inherent estimates actual results may differ estimates company aware reasonably likely events circumstances would result different amounts reported would material impact results operations financial condition reclassifications certain reclassifications made prior year amounts conform current year presentation acquisition july company completed acquisition rosetta inpharmatics inc rosetta leading informational genomics company taxfree reorganization rosetta designed developed several unique technologies efficiently analyze merck co inc annual report table contents gene data predict medical compounds interact different kinds cells body therefore allowing merck scientists precisely select drug targets potentially accelerate development process acquisition accounted purchase method accordingly rosettas results operations included companys since acquisition date pro forma information provided transaction material impact companys results operations financial position accordance may agreement plan merger agreement share outstanding rosetta stock converted shares merck stock resulting issuance company approximately million shares common stock aggregate purchase price transaction approximated million including million common share value million representing employee stock options valued agreement date million estimated transaction fees allocation purchase price resulted tangible assets million consisting primarily cash shortterm investments intangible assets million liabilities assumed million including deferred tax liabilities million associated intangible assets goodwill totaling million intangibles weighted average useful life approximating five years aggregate major class include million patent rights million contractual agreements accordance fas goodwill associated rosetta acquisition amortized joint ventures equity method affiliates merck entered agreement astra ab astra develop market astras products royaltybearing license companys total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby company acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns recorded equity income affiliates aggregated million million million respectively astrazeneca merger triggers partial redemption mercks limited partnership interest upon redemption azlp distribute kbi amount based primarily multiple mercks annual revenue derived sales former astra usa inc products three years prior redemption limited partner share agreed value conjunction restructuring payment million deferred astra purchased option asset option buy mercks interest kbi products excluding gastrointestinal medicines prilosec nexium asset option exercisable exercise price equal net present value march projected future pretax revenue received company kbi products appraised value merck also right require astra purchase interest appraised value addition company granted astra option buy mercks common stock interest kbi exercise price based net present value estimated future net sales prilosec nexium option exercisable two years astras purchase mercks interest kbi products astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment subject trueup calculation may require repayment portion amount trueup amount directly dependent fair market value astra product rights retained company accordingly recognition contingent income deferred realizable amount determinable anticipated prior provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value payment trueup amount occur astrazenecas purchase mercks interest kbi products contingent upon exercise either mercks option astrazenecas option therefore payment appraised value may may occur merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned venture expanded europe canada sales product marketed joint venture million million million merck co inc annual report table contents merck pasteur mrieux connaught aventis pasteur established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales million million million merck rhonepoulenc aventis combined animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species merial sales billion billion may company scheringplough corporation scheringplough entered agreements create separate equally owned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas december cholesterolmanagement partnership agreements expanded include countries world excluding japan october ezetimibe first new class cholesterollowering agents approved us zetia germany ezetrol partnerships also pursuing development marketing zetia oncedaily combination tablet zocor sales ezetimibe totaled million january merckscheringplough pharmaceuticals reported results phase iii clinical trials fixed combination tablet containing singulair claritin scheringploughs nonsedating antihistamine demonstrate sufficient added benefits treatment seasonal allergic rhinitis investments affiliates accounted using equity method including joint ventures totaled billion december billion december amounts reported assets dividends distributions received affiliates million million million financial instruments upon adoption financial accounting standards board statement accounting derivative instruments hedging activities fas january company recorded favorable cumulative effect accounting change million tax comprehensive income loss representing mark fair value purchased local currency put options see note cumulative effect accounting change recorded net income significant foreign currency risk management us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated third party sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows fully offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows first four months changes options intrinsic value deferred accumulated comprehensive income aoci recognition hedged anticipated revenue amounts associated option time value excluded designated hedge relationship marked fair value earnings significant effective may permitted fas implementation guidance finalized june designated hedge relationship based total changes options cash flows accordingly entire fair value change options deferred aoci reclassified sales hedged anticipated revenue recognized hedge relationship perfectly effective therefore hedge ineffectiveness recorded fair values purchased currency options reported accounts receivable assets primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived netassets merck routinely enters contracts fully offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts limited basis merck co inc annual report table contents deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level foreign currency denominated monetary assets liabilities remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company also uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates changes fair value hedged securities due fluctuations spot rates offset income expense net fair value changes forward contracts attributable spot rate fluctuations hedge ineffectiveness material changes contracts fair value due spotforward differences excluded designated hedge relationship recognized income expense net amounts significant years ended december fair values forward exchange contracts reported following four balance sheet line items accounts receivable current portion gain position assets noncurrent portion gain position accrued current liabilities current portion loss position deferred income taxes noncurrent liabilities noncurrent portion loss position interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk company entered fiveyear threeyear million notional amount payfloating receivefixed interest rate swap contracts designated hedges fair value changes million fiveyear threeyear fixed rate notes attributable changes benchmark london interbank offered rate libor swap rate swaps effectively convert fixed rate obligations floating rate instruments fair value changes notes fully offset interest expense fair value changes swap contracts company also party sevenyear combined interest rate currency swap contract entered converts variable rate foreign currency denominated investment variable rate us dollar investment portion contract terminated conjunction sale portion related asset immaterial impact net income interest rate component swap designated hedge currency swap component designated hedge changes fair value investment attributable exchange accordingly changes fair value investment due fluctuations spot rates offset income expense net fair value changes currency swap hedge ineffectiveness significant similar fiveyear swap contract matured related asset sold immaterial impact net income june medco health entered two swapbased rate lock agreements hedged benchmark interest rates associated anticipated july issuances million fiveyear tenyear fixed rate notes notes issued concurrently subsequent completion proposed initial public offering medco health shares swapbased contracts designated hedges variability cash flows future semiannual interest payments anticipated debt offerings due changes libor swap benchmark interest rate period prior expected issuances losses contracts upon maturity totaled approximately million end second quarter probable specific hedged forecasted transactions would occur within two months dates originally specified therefore amount charged income expense net fair values contracts reported accounts receivable assets accrued current liabilities deferred income taxes noncurrent liabilities fair value financial instruments summarized carrying values fair values companys financial instruments december fair values estimated based market prices available dealer quotes carrying fair carrying fair value value value value assets cash cash equivalents shortterm investments longterm investments purchased currency options forward exchange contracts currency swap interest rate swaps liabilities loans payable current portion longterm debt longterm debt forward exchange contracts merck co inc annual report table contents summary carrying values fair values companys investments december follows carrying fair carrying fair value value value value availableforsale debt securities equity securities heldtomaturity securities summary december gross unrealized gains losses companys availableforsale investments recorded net tax minority interests aoci follows gross unrealized gross unrealized gains losses gains losses debt securities equity securities availableforsale debt securities heldtomaturity securities maturing within one year totaled billion million respectively december remaining debt securities billion mature within five years december million million respectively heldtomaturity securities maturing set million million respectively nontransferable note obligations due issued company concentrations credit risk part ongoing control procedures company monitors concentrations credit risk associated corporate issuers securities financial institutions conducts business credit risk minimal credit exposure limits established avoid concentration single issuer institution three drug wholesalers represented aggregate approximately onefifth companys accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost reduction lifo cost inventories valued lifo method comprised approximately inventories december respectively intangibles intangibles december consisted customer relationshipsmedco health patents product rights total acquired cost customer relationshipsmedco health patents product rights total accumulated amortization aggregate amortization expense recorded materials production expense income expense net totaled million million million estimated aggregate amortization expense next five years follows million million million million million loans payable longterm debt commitments loans payable december consisted primarily billion billion respectively commercial paper borrowings million notes annual interest rate resets final maturity annual basis notes either repurchased holders option remarketing agent remarketed redeemed company december loans payable also reflected million million respectively longdated notes subject repayment option holders annual basis weighted average interest rate borrowings december respectively longterm debt december consisted astra note due notes due notes due euronotes due debentures due debentures due variable rate borrowing due debentures due december company party interest rate swap contracts effectively convert fixed rate notes floating rate instruments see note december consisted primarily million borrowings variable rates averaging respectively december million million borrowings subject repayment option holders beginning respectively years also consisted foreign borrowings varying rates merck co inc annual report table contents aggregate maturities longterm debt next five years follows million million billion million million rental expense companys operating leases net sublease income million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable company including medco health party number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states alleging conspiracies restraint trade challenging pricing andor purchasing practices company medco health respectively significant number pharmaceutical companies wholesalers also sued similar litigation actions except several actions pending state courts consolidated pretrial purposes united states district court northern district illinois company several defendants finalized agreement settle federal class action alleging conspiracy represents single largest group retail pharmacy claims since time company entered settlements satisfactory terms october judicial panel multidistrict litigation panel determined consolidated pretrial proceedings federal district court chicago substantially completed panel ordered federal antitrust conspiracy cases several settled company returned federal district courts case originally filed cases returned courts many since transferred federal court brooklyn new york proceedings company engaged conspiracy admission wrongdoing made included settlement agreements feasible predict final outcome remaining proceedings opinion company proceedings ultimately result liability would material adverse effect companys financial position results operations liquidity number federal state lawsuits involving individual claims well purported class actions filed company respect vioxx lawsuits also name defendants pfizer inc pharmacia corporation market competing product lawsuits include allegations regarding gastrointestinal bleeding cardiovascular events company believes lawsuits completely without merit vigorously defend company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella trivalent vaccines measles mumps rubella including companys mmr ii company believes lawsuits completely without merit vigorously defend company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties prps may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs worldwide survey initially performed assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated estimates extent contamination site initially made preinvestigation stage liabilities potential cost remediation accrued time definitive information became available course investigations andor remedial efforts site estimates refined accruals adjusted accordingly estimates related accruals continue refined annually managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries insurers parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year recently company medco health agreed settle class action basis series lawsuits asserting violations theemployee retirement income security act erisa company medco health certain plaintiffs counsel filed merck co inc annual report table contents settlement federal district court new york plaintiffs six pharmaceutical benefit plans medco health pharmacy benefit manager filed cases proposed class action settlement agreed plaintiffs five initial six cases gruer cases filed medco health company proposed settlement court yet preliminarily approved company medco health agreed pay million medco health agreed change continue certain specified business practices period five years financial compensation intended benefit members settlement class includes among others erisa plans medco health administered pharmacy benefit time since december settlement preliminarily approved class member plans opportunity participate opt settlement court also schedule hearing purpose determining fairness settlement class members one initial plaintiffs group lawyers filed additional erisa lawsuits company medco health expected oppose settlement settlement becomes final district court grants final approval appeals resolved medco health company agreed proposed settlement order avoid significant cost distraction protracted litigation gruer cases similar claims pharmaceutical benefit managers pending cases alleged medco health treated fiduciary erisa medco health breached fiduciary duty benefit plans amended complaints gruer cases also alleged company medco health violated erisa using medco health increase companys market share entering certain prohibited transactions favor companys products plaintiffs demanded medco health company turn unlawfully obtained profits trust set benefit plans one plaintiffs indicated may amend complaint medco health others allege violations sherman act clayton act various states antitrust laws due alleged conspiracies suppress price competition unlawful combinations allegedly resulting higher pharmaceutical prices similar complaints medco health company also assert claims breach fiduciary duty erisa filed six additional actions plan participants purportedly behalf plans actions similarlysituated self funded plans class action status sought one actions plans could decide opt participate proposed settlement discussed parties lawsuits amended complaint one actions alleges various activities company medco health violate federal state racketeering laws addition proposed class action complaint medco health company also filed trustees one benefit plan complaints actions rely many theories litigation discussed two lawsuits based many allegations also pending medco health federal court california state court new jersey theory liability former action company also defendant based california statute prohibiting unfair business practices plaintiff purports sue behalf general public california seeks injunctive relief disgorgement revenues allegedly improperly received company medco health theory liability new jersey action based new jersey consumer protection statute plaintiff purports represent class similarlysituated non erisa plans seeks compensatory treble damages new jersey court dismissed new jersey action may reinitiated certain circumstances medco health company believe cases completely without merit medco health fiduciary within meaning erisa neither company medco health violated erisa california unfair business practices law new jersey consumer protection law medco health company intend vigorously defend remaining claims various legal proceedings involving company medco health principally product liability intellectual property suits involving company pending feasible predict outcome proceedings opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company medco health addition time time federal state regulators seek information practices industries company medco health operate feasible predict outcome requests information company medco health expect inquiries material adverse effect financial position liquidity results operations company medco health preferred stock subsidiary companies march whollyowned subsidiary company issued billion par value variable rate preferred units units redeemable par value plus accrued dividends option issuer time also redeemable option holders march end fiveyear interval thereafter addition certain provisions could lead companys subsidiary decide redeem preferred units credit ratings companys unsecured senior debt obligations fall specified levels likelihood company believes remote preferred securities held subsidiary level included minority interests consolidated financial statements connection restructuring ami see note company assumed billion par value preferred stock obligation dividend rate per annum carried kbi included minority interests small portion preferred stock carried kbi convertible kbi common shares none preferred securities convertible companys common shares therefore included common shares issuable purposes computing earnings per common share assuming dilution see note stockholders equityother paidin capital increased million million million respectively merck co inc annual report table contents increase includes million resulting shares issued equivalent employee stock options assumed connection rosetta acquisition see note remaining increases primarily reflect impact shares issued upon exercise stock options related income tax benefits summary treasury stock transactions shares millions follows shares cost shares cost shares cost balance jan purchases issuances balance dec issued primarily stock option plans december million shares preferred stock without par value authorized none issued stock option plans company stock option plans employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders option grants beginning generally vest ratably three years grants prior generally vest five years options expire ten years date grant companys stock option plan employees also provides granting performancebased stock awards connection mercks acquisition rosetta medco healths acquisition provantage health services inc stock options outstanding acquisition dates converted options purchase shares company common stock equivalent value summarized information relative companys stock option plans shares thousands follows average number shares price outstanding december granted exercised forfeited equivalent options assumed outstanding december granted exercised forfeited equivalent options assumed outstanding december granted exercised forfeited outstanding december weighted average exercise price number shares average price options exercisable december million shares million shares million shares respectively december million shares million shares respectively available future grants terms plans summarized information stock options outstanding exercisable december shares thousands follows outstanding exercisable exercise price number average average number average range shares life price shares p rice weighted average contractual life remaining years weighted average exercise price pension postretirement benefit plans net cost companys pension plans consisted following components years ended december service cost interest cost expected return plan assets net amortization net pension cost net pension cost attributable international plans included table million million million net cost postretirement benefits pensions consisted following components years ended december service cost interest cost expected return plan assets net amortization curtailment net postretirement benefit cost cost health care life insurance benefits active employees million million million merck co inc annual report table contents summarized information changes plan assets benefit obligation follows postretirement pension benefits benefits fair value plan assets january actual return plan assets company contributions benefits paid plan assets fair value plan assets december benefit obligation january service cost interest cost actuarial losses benefits paid plan amendments benefit obligation december fair value international pension plan assets included preceding table billion million pension benefit obligation international plans included table billion billion reconciliation plans funded status net asset liability recognized december follows postretirement pension benefits benefits plan assets less benefit obligation unrecognized net loss unrecognized plan changes unrecognized transitional net asset net asset liability recognized assets accrued current liabilities deferred income taxes noncurrent liabilities accumulated comprehensive loss pension plans benefit obligations excess plan assets december fair value plan assets billion billion respectively benefit obligation billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets million million respectively accumulated benefit obligation billion million respectively assumptions used determining us plan information follows pension postretirement benefits december discount rate expected rate return plan assets salary growth rate company reassesses benefit plan assumptions regular basis company changed expected rate return holding assumptions constant net pension postretirement benefit cost companys us plans expected increase approximately million approximately million attributable lower discount rate december million attributable lower expected rate return three years presented international pension plan assumptions ranged discount rate expected rate return plan assets salary growth rate unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization unrecognized net losses companys us plans december expected increase net pension postretirement benefit cost approximately million growing million december company minimum pension liability million million respectively representing extent accumulated benefit obligation exceeded plan assets certain companys pension plans increase minimum pension liability recorded comprehensive income loss assets primarily reflects increase benefit obligation attributable reduction discount rate assumption well certain plans decrease fair value plan assets health care cost trend rate postretirement benefit plans december rate expected decline eightyear period one percentage point change health care cost trend rate would following effects one percentage point increase decrease effect total service interest cost components effect benefit obligation merck co inc annual report table contents company changed participant contributions eligibility requirements attribution methodology certain postretirement benefit plans amendments reduced benefit obligation million generated curtailment gain million income expense net years ended december interest income interest expense exchange gains minority interests amortization goodwill intangibles net minority interests include third parties share exchange gains losses arising translation financial statements us dollars reduced minority interests reflect lower dividends variable rate preferred units see note decreased minority interest expense associated banyu pharmaceutical co ltd banyu january company wholly owned subsidiary msd japan co ltd launched tender offer acquire estimated aggregate purchase price billion remaining common shares banyu already tender offer closes march conditional company receiving least million common shares bring share ownership banyu approximately decreased amortization goodwill intangibles reflects adoption fas see note interest paid million million million taxes income reconciliation companys effective tax rate us statutory rate follows tax rate amount us statutory rate applied pretax income differential arising foreign earnings tax exemption puerto rico operations state taxes domestic companies contributed approximately consolidated pretax income taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation advance payment equity investments pensions opeb accrued rebates compensation related environmental related subtotal valuation allowance total deferred taxes net deferred tax liabilities recognized prepaid expenses taxes assets income taxes payable deferred income taxes noncurrent liabilities income taxes paid billion billion billion respectively stock option exercises reduced income taxes paid million million million respectively december foreign earnings billion domestic earnings million retained indefinitely subsidiary companies reinvestment provision made income taxes would payable upon distribution earnings practicable determine amount related unrecognized deferred income tax liability earnings include income manufacturing operations ireland taxexempt taxed thereafter addition company domestic subsidiaries operating puerto rico tax incentive grant expires merck co inc annual report table contents companys federal income tax returns audited earnings per share weighted average common shares used computations basic earnings per common share earnings per common share assuming dilution shares millions follows years ended december average common shares outstanding common shares issuable average common shares outstanding assuming dilution issuable primarily stock option plans comprehensive income upon adoption fas january company recorded favorable cumulative effect accounting change million comprehensive income loss amount represented mark fair value purchased local currency put options maturing throughout hedged anticipated foreign currency denominated sales period december million deferred loss associated options maturing next months hedge anticipated foreign currency denominated sales period components comprehensive income loss follows pretax tax tax year ended december net unrealized loss derivatives net income realization derivatives net unrealized gain investments net income realization investments minimum pension liability year ended december cumulative effect accounting change net unrealized gain derivatives net income realization derivatives net unrealized gain investments net income realization investments minimum pension liability year ended december net unrealized gain investments net income realization investments minimum pension liability net applicable minority interest components accumulated comprehensive loss income follows december net unrealized loss gain derivatives net unrealized gain investments minimum pension liability segment reporting companys operations principally managed products services basis comprised two reportable segments merck pharmaceutical includes products marketed either directly joint ventures medco health merck pharmaceutical products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations institutions medco health revenues consist principally sales prescription drugs managed prescription drug programs either home delivery pharmacies network contractually affiliated retail pharmacies well services provided programs help clients control cost enhance quality prescription drug benefits offered members medco healths clients include blue crossblue shield plans managed care organizations insurance carriers thirdparty benefit plan administrators employers federal state local government agencies unionsponsored benefit plans medco health one client represented approximately medco health net revenues medco health revenues following table reflect sales prescription drugs drug spend basis including amounts reportable revenues consolidated statement income accordance companys internal management reporting presented chief operating decision maker merck co inc annual report table contents includes nonreportable human animal health segments revenues profits segments follows merck medco pharmaceutical health total year ended december segment revenues segment profits included segment profits equity income loss affiliates depreciation amortization year ended december segment revenues segment profits included segment profits equity income loss affiliates depreciation amortization year ended december segment revenues segment profits included segment profits equity income loss affiliates depreciation amortization segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker company allocate vast majority indirect production costs research development expenses general administrative expenses predominantly related merck pharmaceutical business well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included marketing segment profits vast majority goodwill amortization intangibles amortization predominantly related medco health business well cost financing capital employed also allocated internal management reporting therefore included marketing segment profits reconciliation total segment revenues consolidated sales follows years ended december segment revenues revenues adjustments revenues primarily comprised miscellaneous corporate revenues sales related divested products businesses supply sales adjustments represent elimination receipts reported revenues internal management reporting reportable revenues gaap consolidated sales included billion billion billion revenues derived united states billion billion billion revenues derived foreign operations respectively reconciliation total segment profits consolidated income taxes follows years ended december segment profits profits adjustments unallocated interest income interest expense equity income loss affiliates depreciation amortization research development expenses net profits primarily comprised miscellaneous corporate profits well operating profits related divested products businesses supply sales adjustments represent elimination effect double counting certain items income expense equity income loss affiliates includes taxes paid joint venture level portion equity income reported segment profits expenses net include expenses corporate manufacturing cost centers miscellaneous income expense net net property plant equipment included billion billion billion assets located united states billion billion billion assets located outside united states respectively company disaggregate assets products services basis internal management reporting therefore information presented january company announced plans establish medco health separate publiclytraded company medco health converted limited liability company delaware corporation may changed name merckmedco managed care llc medco health solutions inc july merck announced due solely market conditions postponing initial public offering ipo shares medco health withdrew associated equity registration statement merck remains fully committed establishment medco health separate publiclytraded company intends complete separation mid subject market conditions merck co inc annual report table contents managements report primary responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization establishing internal controls management weighs costs systems benefits believes systems provide staff internal auditors regularly monitors adequacy application internal controls worldwide basis insure personnel continue understand system internal controls procedures policies concerning good prudent business practices company periodically conducts managements stewardship program key management financial personnel program reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition ethical business practices program implemented reinforce companys longstanding commitment high ethical standards conduct business independent public accountants audited companys consolidated financial statements described report although audits designed purpose forming opinion internal controls companys accounting systems procedures internal controls subject testing auditing procedures sufficient enable independent public accountants render opinion companys financial statements recommendations internal auditors independent public accountants reviewed management control procedures implemented revised appropriate respond recommendations material control weaknesses brought attention management managements opinion year ended december internal control system strong accomplished objectives discussed herein financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included companys filing raymond v gilmartin judy c lewent chairman president executive vice president chief executive officer chief financial officer president human health asia audit committees report board directors audit committee dismissed arthur andersen llp companys independent public accountants february engaged pricewaterhousecoopers llp serve companys independent public accountants fiscal year audit committee comprised independent directors met independent public accountants management internal auditors assure carrying respective responsibilities audit committee discussed received letter independent public accountants confirming independence independent public accountants internal auditors full access committee including regular meetings without management present audit committee met independent public accountants discuss fees scope results audit work including adequacy internal controls quality financial reporting committee also discussed independent public accountants judgments regarding quality acceptability companys accounting principles clarity disclosures degree aggressiveness conservatism accounting principles underlying estimates audit committee reviewed discussed audited financial statements management recommended board directors financial statements included companys filing securities exchange commission heidi g miller lawrence bossidy chairperson thomas e shenk samuel thier merck co inc annual report table contents compensation benefits committees report compensation benefits committee comprised independent directors approves compensation objectives policies employees sets compensation companys executive officers committee seeks ensure rewards closely linked company division team individual performances committee also seeks ensure compensation benefits set levels enable merck attract retain highquality employees committee views stock ownership vehicle align interests employees companys stockholders consistent longterm focus inherent companys rdbased pharmaceutical business policy committee make high proportion executive officer compensation dependent longterm performance enhancing stockholder value lawrence bossidy william g bowen chairperson johnnetta b cole william n kelley reports independent public accountants stockholders board directors merck co inc opinion accompanying consolidated balance sheet december related consolidated statements income retained earnings comprehensive income cash flows present fairly material respects financial position merck co inc subsidiaries december results operations cash flows year ended conformity accounting principles generally accepted united states america financial statements responsibility companys management responsibility express opinion financial statements based audit conducted audit statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audit provides reasonable basis opinion financial statements merck co inc december two years period ended december prior additional disclosures notes audited independent accountants ceased operations independent accountants expressed unqualified opinion financial statements report dated january discussed note financial statements company adopted statement financial accounting standards sfas goodwill intangible assets effective january discussed financial statements merck co inc december two years period ended december audited independent accountants ceased operations described note financial statements revised include transitional disclosures required sfas goodwill intangible assets adopted company january audited transitional disclosures contained notes opinion transitional disclosures notes appropriate however engaged audit review apply procedures financial statements company respect disclosures accordingly express opinion form assurance financial statements taken whole florham park pricewaterhousecoopers llp new jersey january following copy audit report previously issued arthur andersen llp connection merck co incs filing annual report year ended december audit report reissued arthur andersen llp connection filing companys annual report see exhibit discussion consolidated balance sheet december consolidated statements income retained earnings comprehensive income cash flows year ended december included accompanying financial statements stockholders board directors merck co incwe audited accompanying consolidated balance sheet merck co inc new jersey corporation subsidiaries december related consolidated statements income retained earnings comprehensive income cash flows three years period ended december financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits accordance auditing standards generally accepted united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects financial position merck co inc subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states new york new york arthur andersen llp january merck co inc annual report table contents selected financial data merck co inc subsidiaries millions except per share amounts results year sales materials production costs marketing administrative expenses research development expenses acquired research equity income loss affiliates gains sales businesses restructuring charge income expense net income taxes taxes income net income basic earnings per common share earnings per common share assuming dilution dividends declared dividends paid per common share capital expenditures depreciation yearend position working capital property plant equipment net total assets longterm debt stockholders equity financial ratios net income sales average total assets yearend statistics average common shares outstanding millions average common shares outstanding assumingdilution millions number stockholders record number employees amounts include impact medco health acquisition november results operations exclude cumulative effect accounting changes increase due inclusion medco health employees merck co inc annual report exhibit merck co inc subsidiaries subsidiaries set forth business name stated subsidiary subsidiary indicated indentation immediate parent voting securities subsidiaries named owned directly indirectly company except otherwise indicated country state name incorporation chibret denmark cm delaware llc delaware hangzhou msd pharmaceutical company limited china hawk falcon llc delaware international indemnity ltd bermuda johnson johnsonmerck consumer pharmaceuticals company new jersey mcm vaccine co pennsylvania merck company incorporated delaware merck sh inc delaware merial limitedllc great britain delaware british united turkeys limited great britain turkey research development limited great britain merck capital resources inc delaware msd technology lp delaware merck finance co inc delaware merck hamilton inc california merck capital ventures llc delaware merck cardiovascular health company nevada msp distribution services c llc nevada msp marketing services c llc nevada merck enterprises canada ltd canada merck foreign sales corporation ltd bermudamerck holdings inc delaware chippewa holdings llc delaware algonquin sarl luxembourg frosst laboratories inc delaware frosst portuguesaprodutos farmaceuticos lda portugal istituto gentili spainc italydelaware kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware merck borinquen holdings inc delaware merck sharp dohme quimica de puerto rico inc delaware merckmedco holdings ii corp delaware cloverleaf international holdings sa luxembourg brc ltd bermuda coordinated patient care scandinavia norway infodoc norway infodoc international norway medco holdings de rl de cv mexico medco de mexico managed care de rl de cv mexico medco servicios de mexico de rl de cv mexico farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal fontelaborprodutos farmaceuticos lda portugal gestion integrada de salud analisis de resultados evidencia medichip sl spain merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme australia pty limited australia amrad pharmaceuticals pty ltd australia merck sharp dohme finance europe limited great britain merck sharp dohme bv netherlands abello farmacia sl spain financiere msd sas france aventis pasteur msd gestion sa france aventis pasteur msd snc france aventis pasteur msd denmark aventis pasteur msd gmbh austria aventis pasteur msd gmbh germany aventis pasteur msd ltd great britain aventis pasteur msd ltd ireland aventis pasteur msd nvsa belgium aventis pasteur msd sa spain aventis pasteur msd spa italy pasteur vaccins sa france laboratoires martinjohnson johnsonmsd sas france laboratoires merck sharp dohmechibret snc france msd nippon holdings bv netherlands banyu pharmaceutical company ltd japan banyuasc co ltd japan nippon merckbanyu co ltd japan laboratorios biopat sa spain laboratorios chibret sa spain laboratorios frosst sa spain laboratorios neurogard sa spain merck sharp dohme gmbh austria merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme de mexico sa de cv mexico merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy centra medicamenta otc spa italy istituto di richerche di biologia molecolare spa italy msd proprietary limited south africa msd sharp dohme gmbh germany chibret pharmazeutische gmbh germany dieckmann arzneimittel gmbh germany woelm pharma gmbh co germany msd chibropharm gmbh germany msd unterstutzungskasse gmbh germany varipharm arzneimittel gmbh germany sharp dohme sa spain merck sharp dohme chibret ag switzerland merck sharp dohme de venezuela srl venezuela merck sharp dohme holdings limited great britain charles e frosst uk limited great britain merck sharp dohme limited great britain johnson johnsonmsd consumer pharmaceuticals limited great britain msd foundation limited great britain thomas morson son limited great britain merck sharp dohme idea inc switzerland merck sharp dohme doo croatia merck sharp dohme tunisie sar l tunisia merck sharp dohme sweden ab sweden merck sharp dohme trading service limited liability company hungary msd ireland holdings sa luxembourg european insurance risk excess limited ireland fregenal holdings sa panama frosst iberica sa spain laboratorios abello sa spain laboratorios quimicofarmaceuticos chibret lda portugal merck sharp dohme de espana sa spain merck sharp dohme limitada portugal msd finance bv netherlands msd overseas manufacturing co bermuda blue jay investments cv netherlands msd ireland investment ltd bermuda msd latin america services ltd bermuda msd overseas manufacturing co ireland ireland tradewinds manufacturing srl barbados msd technology singapore pte ltd singapore msp singapore company llc delaware msdsp ltd great britain msdessex gmbh switzerland msp singaporesub llc delaware msd warwick manufacturing ltd bermuda msd somerset ltd bermuda crosswinds bv netherlands merck sharp dohme ireland ltd bermuda msd pembroke ltd bermuda merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda transrow manufacturing ltd bermuda neopharmed spa italy msd norge norway msd ventures singapore pte ltd singapore ruskin limited bermuda suomen msd oy finland kiinteisto oy viistotie finland merck frosst canada co canada maple leaf holdings srl barbados merck frosst canada ltd canada msd japan co ltd japan merck sharp dohme ia corp delaware merck sharp dohme argentina inc delaware msd korea ltd koreadelaware merck sharp dohme ilaclari limited sirketi turkey merck sharp dohme farmaceutica ltda brazil prodome quimica e farmaceutica ltda brazil merck sharp dohme international limited bermuda merck sharp dohme asia limited hong kong merck sharp dohme china limited hong kong merck sharp dohme sas france merck sharp dohme international services bv netherlands merck sharp dohmelebanon sal lebanon merck sharp dohme llc russian federation merck sharp dohme middle east limited cyprus merck sharp dohme pakistan limited pakistan merck sharp dohme sarl morocco merck technology us company inc nevada msp technology us company llc delaware merck ventures inc delaware msd lakemedel scandinavia aktiebolog sweden readington holdings inc new jersey stellarx inc nevada telerx marketing inc pennsylvania merck institute vaccinology delaware merck investment co inc delaware merck liability management company delaware merck lmc cash management bermuda ltd bermuda merck lmc cash management inc delaware medco health solutions inc delaware dmmg llc delaware medcocal inc california medcohealthcom llc new jersey medco containment insurance company new jersey new jersey medco containment insurance company new york new york medco containment life insurance company pennsylvania medco health llc delaware medco health solutions columbus north ltd ohio medco health solutions columbus west ltd ohio medco health solutions henderson nevada llc delaware medco health solutions hidden river lc florida medco health solutions las vegas inc nevada medco health solutions mechanicsburg llc pennsylvania medco health solutions netpark llc delaware medco health solutions north versailles llc pennsylvania medco health solutions parsippany llc new jersey medco health solutions richmond llc virginia medco health solutions sabal park lc florida medco health solutions spokane inc washington medco health solutions texas llc texas medco health solutions willingboro llc new jersey merckmedco willingboro urban renewal llc new jersey merckmedco rx services florida lc florida merckmedco rx services massachusetts llc massachusetts merckmedco rx services new york llc new york merckmedco rx services oklahoma llc oklahoma mw holdings llc delaware njre llc new jersey national rx services inc missouri missouri national rx services inc ohio ohio new york paid independent practice association llc new york nrx federal corp delaware paid direct inc delaware provantage health services inc delaware bravell inc wisconsin pharmark corporation delaware provantage mail services inc minnesota provmed llc wisconsin pvhs inc delaware replacement distribution center inc ohio rxhub llc delaware institute effectiveness research llc delaware systemed llc delaware xceleron health llc delaware merck resource management inc delaware merck respiratory health company nevada msp distribution services r llc nevada msp marketing services r llc nevada merck sharp dohme europe inc delaware merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme new zealand limited new zealand merck sharp dohme overseas finance nv neth antilles merck sharp dohme panama sa panama merck sharp dohme peru srl peru merck sharp dohme philippines inc philippines msd international holdings inc delaware rosetta inpharmatics llc delaware less exhibit notice regarding consent arthur andersen llp section securities act amended securities act provides case part registration statement part became effective contained untrue statement material fact omitted state material fact required stated therein necessary make statements therein misleading person acquiring security unless proved time acquisition person knew untruth omission may sue among others every accountant consent named prepared certified part registration statement prepared certified report valuation used connection registration statement respect statement registration statement report valuation purports prepared certified accountant companys consolidated financial statements years ended included audited arthur andersen llp arthur andersen issued audit report dated january consolidated financial statements audit report copy included incorporated reference companys previously filed registration statements form nos form nos collectively registration statements february company dismissed arthur andersen independent public accountants engaged pricewaterhousecoopers llp serve companys independent public accountants fiscal year company understands staff securities exchange commission taken position accept consents arthur andersen engagement partner manager companys audit longer arthur andersen engagement partner manager companys audit longer arthur andersen arthur andersen ceased practicing securities exchange commission result company unable obtain arthur andersens written consent incorporation reference registration statements audit report respect companys financial statements circumstances rule securities act permits company file incorporated reference registration statements without written consent arthur andersen arthur andersen consented inclusion audit report registration statements arthur andersen liability section securities act untrue statements material fact contained financial statements audited arthur andersen incorporated reference registration statements omission material fact required stated therein accordingly investors able assert claim arthur andersen section securities act purchases securities registration statements made date exhibit power attorney undersigned hereby appoint celia colbert kenneth c frazier severally hisher true lawful attorney attorneys execute behalf undersigned whether behalf company officer director thereof attesting seal company otherwise annual report merck co inc fiscal year ended december securities exchange act including amendments thereto